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SUMMARY
Purpose. Healon (sodium hyaluronate 1%), a viscoelastic material widely used 
in ophthalmic surgery, may exacerbate the potentially harmful early intraocular 
pressure (IOP) rise observed postoperatively in cataract surgery. The results of 
in vitro studies demonstrate that such IOP elevations may be due to obstruction 
of the aqueous humour outflow pathways. Therefore Healon- induced IOP rises 
might be preventable if this biopolymer could be depolymerized into smaller 
molecules which could be easily cleared by the outflow pathways. Ascorbic 
acid (AA) depolymerizes hyaluronic acid in vitro in a concentration-dependent 
manner at concentrations of AA which are normally present in the aqueous 
humour. In the early postoperative period, aqueous AA levels are probably 
decreased due to damaging effects of surgical trauma on the blood-aqueous 
barrier (BAB). Furthermore, recent reports suggest that Healon exacerbates the 
postsurgical BAB breakdown. Collectively, these results suggest that the BAB 
breakdown occurring during surgery may result in a drop in the concentrations 
of aqueous humour ascorbate to levels too low to effectively depolymerize 
Healon. This suggests that if physiological levels of ascorbate could be 
maintained the postoperative Healon-induced IOP rise would be attenuated. 
The purpose of this study was to investigate if Healon-induced IOP rises can be 
attenuated by increasing aqueous AA levels in the aqueous humour in the 
immediate postoperative period. Clinical, animal and in vitro studies were 
conducted to investigate this hypothesis.
Methods and Results. In a pilot study the timecourse of plasma AA levels 
following a single lg dose of ascorbate was investigated in five volunteers. 
Plasma AA peaked within 2-4h and remained high for 3-5h. An initial study
XVIII
was conducted to determine the maximum increase in aqueous AA attainable 
after oral pretreatment with AA in 105 patients undergoing cataract surgery. 
Patients were divided into 5 groups based on the total dose of AA given 
preoperatively (0, 1, 2, 3 or 5g in two divided doses). The maximal aqueous 
AA levels (pg.ml- !) were attained with the 2g dose (643±73; mean±SEM) 
which is approximately two-fold increase over non-pretreated patients. The 
effect of Healon on the postoperative IOP and the effect of AA on the Healon- 
induced IOP rise was then studied in a prospective randomized double-masked 
trial in 76 patients who underwent uncomplicated cataract surgery with and 
without the use of Healon. A total dose of 2g ascorbate or placebo was given 
before surgeiy and IOP was measured at 6 and 24h postoperatively. Healon- 
treated patients were further subdivided in three groups according to the volume 
of Healon used intraoperatively (<0.2ml, 0.2-0.35ml and >0.35ml). AA 
pretreatment did not influence the postoperative rise in IOP in any of the 
Healon groups. A large difference in IOP between operated and contralateral 
control eyes among no Healon and Healon-treated (in whatever volume) 
patients was observed at 6 and 24h. Significant increases in IOP in the operated 
eyes of all groups of patients who received various volumes of Healon were 
observed at 6h postoperatively, except for the group which received <0.2ml 
Healon. Significantly higher IOP rises were observed in the >0.35ml Healon 
than the <0.2 ml Healon, 0.2-0.35ml Healon or no Healon groups at 6h. A 
significantly higher percentage (77%) of patients who received >0.35ml Healon 
exhibited differences in IOP greater than lOmmHg between operated and 
control eyes at 6h as compared with that of no Healon, <0.2ml Healon or 0.2- 
0.35ml Healon groups. At 24h, there was still a high percentage (22%) in the 
>0.35ml Healon group with a difference in IOP greater than lOmmHg while in
XIX
all other groups, IOP returned to preoperative levels. In order to better 
understand the failure of AA pretreatment to prevent the Healon-induced IOP 
elevations, studies were conducted in 52 rabbits to determine whether the 
trauma of surgery may have been responsible for the absence of sufficient levels 
of AA in the aqueous humour postoperatively. In these studies, the effects of 
surgical procedures (corneal incision alone and comeal incision plus lens 
removal) and Healon on aqueous ascorbate concentration were investigated. An 
approximate 50% decrease in aqueous AA levels was observed 2-6h 
postoperatively (without the use of Healon), which persisted at 48h. However, 
an additional (18%) significant drop in AA levels was found in eyes which 
underwent lens removal with the use of Healon intraoperatively. Pretreatment 
with oral AA (50mg/kg body weight, 3h preoperatively) significantly increased 
AA levels, but did not attenuate the surgically- and Healon-induced drops in 
AA concentration at 6 and 48h postoperatively, although plasma AA levels 
remained elevated for about lOh. Aqueous humour and plasma ascorbate levels 
were determined by HPLC in both clinical and animal studies. Since the results 
of these studies suggested that AA levels decrease during surgery even with AA 
pretreatment, experiments were conducted in a human eye model in vitro 
(perfused ocular anterior segments) to determine whether the obstructive effect 
of Healon could be eliminated under conditions where a constant high 
concentration of AA could be obtained. Initial studies were designed to confirm 
that Healon decreases outflow facility. After establishment of a baseline 
outflow facility different concentrations of the commercial preparation of 
Healon (100%, 50% and 10%) in culture medium were perfused in a total of 22 
eyes. The maximum amount of obstruction obtained was 55%, 30% and 12%, 
respectively. A significant decrease in outflow facility was observed with all
XX
Healon solutions in a concentration-related fashion. The obstructive properties 
of Healon were consistent with histological findings. Similar to the Healon- 
induced rises in IOP observed in the clinical studies, Healon-induced reductions 
in outflow facility did not improve when the eyes were perfused in the presence 
of a constant high concentration of AA (lOOOpg.ml- !) studied in 3 pairs of 
human eyes over a period of 6h.
Conclusions. A two-fold increase in aqueous AA levels can be achieved by 
oral administration of AA. Healon-induced IOP rises in the immediate 
postoperative period are dose-related. When more than 0.35ml of Healon is 
used, high IOP rises are observed for at least 24h. Surgery results in a 50% 
decrease in aqueous AA concentrations in the rabbit, and Healon has an 
exacerbating effect on this reduction. Healon reduces outflow facility in a 
dose-related manner and this reduction is not improved in the presence of a high 
concentration of AA. Postoperative Healon-induced IOP rises are not prevented 
by increased levels of aqueous humour ascorbate. Healon is not depolymerized 
by AA in vivo, or if it is, that depolymerization is not sufficient to break 
hyaluronate molecules down to a size compatible with easy egress from the 
anterior chamber.
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PREFACE
The introductory material in the first chapter describes the fundamental 
anatomy and physiology of the anterior segment of the eye relevant to the basic 
hypotheses of this thesis. The literature on hyaluronic acid and the use of 
Healon^ (sodium hyaluronate 1%) in cataract surgery with particular emphasis 
on its exacerbating effect on postoperative intraocular pressure elevation is then 
reviewed. This is followed by a selective review on ascorbic acid 
pharmacology including its capacity to depolymerize hyaluronic acid. The 
central hypothesis along with the rationale, approach and specific aims 
underlying the body of work are then presented in subsequent chapters.
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CHAPTER 1 
INTRODUCTION
1.1 AQUEOUS HUMOUR DYNAMICS
1.1.1 Introduction
The term aqueous humour dynamics refers to the sum total of 
physiological events associated with the production and drainage of aqueous 
humour and the maintenance of normal intraocular pressure (Kaufman, 1985).
The human eye consists essentially of three layers enclosing the 
transparent refractive media (Figure 1). The outermost layer is made up of the 
sclera and cornea. The middle coat is mainly vascular, consisting of the 
choroid, ciliary body and iris. The innermost layer is the retina, containing the 
essential nervous elements responsible for vision - the rods and cones; it is 
continued forward over the ciliary body as the ciliary epithelium (Davson, 
1990). The globe of the eye contains three chambers: the anterior chamber, the 
posterior chamber and the vitreous cavity. The anterior chamber is bounded 
anteriorly by the cornea, posteriorly by the front surface of the iris and the lens, 
and peripherally by the anterior chamber angle. The posterior chamber is 
bounded anteriorly by the iris, posteriorly by the anterior lens capsule and its 
zonule (suspensory ligament of the lens), and peripherally by the ciliary 
processes. The vitreous cavity is the largest cavity of the eye and is bounded 
anteriorly by the lens, zonule and ciliary body, and posteriorly by the retina 
and optic nerve.
The ciliary processes secrete aqueous humour into the posterior chamber 
of the eye. From here, the aqueous humour flows into the anterior chamber 
and leaves the eye by bulk flow via two pathways: (1) the conventional route
2
through the trabecular meshwork and (2) the unconventional or uveoscleral 
route. The chamber-angle tissues offer a certain amount of resistance to the 
outflow of aqueous humour. Intraocular pressure (IOP) builds up due to the 
inflow of aqueous, to a level sufficient to drive fluid through that resistance at 
the same rate at which it is produced. In the glaucomatous eye, this resistance 
is usually high causing elevated IOP, which is associated with damage to the 
optic nerve and subsequent loss in visual field.
1.1.2 The ciliary epithelia
The ciliary body foims a ring along the inner wall of the globe and 
extends from the iris anteriorly to the ora serrata posteriorly. The largest 
component of the ciliary body is smooth muscle that is arranged in three 
bundles: longitudinal, reticular and circular. The ciliary body is anatomically 
divided into two segments: the anterior pars plicata and the smooth posterior 
pars plana. The ciliary processes, approximately 70 in the human, project 
inward from the pars plicata region as radial ridges. They consist of a central 
core of highly vascularised connective tissue surrounded by a double layer of 
epithelium (Figure 2). The two layers face each other apex-to-apex, as a result 
of the invagination of the neuroepithelial layer during embryogenesis (Figure 
3). The inner epithelial layer consists of non- pigmented epithelium (NPE), 
which lies adjacent to the posterior chamber and contains many mitochondria 
and rough and smooth endoplasmic reticulum. Tight junctions are present on 
the apical surfaces of these cells. The outer epithelial layer consists of the
3
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Figure 1 Horizontal section through the human eyeball at the level of the 
optic nerve (Snell and Lemp, 1989).
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Figure 2 Schematic cross-section of the ciliary epithelium of a human 
eye showing its relationship to the capillaries and aqueous humour (Fatt 
and Weissman, 1992).
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pigmented epithelium (PE). It rests on the stromal core. The pigmented 
epithelium contains melanosomes but is relatively poor in other intracellular 
organelles. The cells of this layer are coupled to each other and the NPE by 
gap junctions (Figure 4).
1.1.3 Production of aqueous humour
Aqueous humour is derived from the ocular blood supply and is 
essentially a modified filtrate of blood serum. Aqueous humour enters the 
posterior chamber via the ciliary processes. The production of aqueous 
humour occurs through a combination of diffusion, ultrafiltration and active 
transport/secretion (Caprioli, 1987, 1992). It is now well accepted that active 
transport of certain solutes by the ciliary epithelia is the most important process 
in the formation of aqueous humour. Specific transport systems of the NPE 
secrete potassium chloride, bicarbonate, some amino acids, glucose, ascorbic 
acid and some organic compounds into the posterior chamber. The active 
solute pump sets up a concentration gradient that forces an osmotic flow of 
water into the posterior chamber. The major transport system is the 
membrane-bound enzyme complex sodium-potassium adenosine triphosphatase 
(Na+/K+ATPase) which is located on the NPE membrane and is found in 
highest concentrations along the lateral cellular interdigitations. When this 
enzyme system is inhibited by ouabain, formation of aqueous humour is 
reduced by about 70% (Cole, 1977). Carbonic anhydrase is also involved in 
active transport in the ciliary body. Inhibition of carbonic anhydrase decreases 
the secretory activity of the ciliary epithelium (Garg and Oppelt, 1970; Maren, 
1977).
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Figure 3 The apex-to-apex relation of the two layers of cells of the 
human ciliary epithelium (Davson, 1990).
Schematic diagram of human non-pigmented and pigmented epithelial 
cells showing intracellular organelles and tight and gap junctions.
DES=desmosomes; BI=basal infoldings; BM=basement membrane; CC=ciliary 
channels; FE=fenestrated capillary endothelium; GJ=gap junction; 
MEL=melanosome; MIT^mitochondrion; RBC=red blood cell; RER=rough 
endoplasmic reticulum,;TJ=tight junction (Caprioli, 1992).
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The NPE probably plays the dominant role in aqueous humour formation, 
but the exact nature of its interaction with the PE remains unclear.
1.1.4 Composition of aqueous humour
The volume of aqueous humour in the anterior and posterior chambers of 
the human eye is about 200-250pl and 60pl, respectively and turns over 
approximately once every lOOmin (Caprioli, 1992).
The aqueous humour contains no cellular components, but has most of 
the small molecular weight electrolyte and nutrient constituents of serum. In 
addition, some constituents (eg, ascorbate) are in much higher concentration 
than in serum, suggesting that they are actively transported into the aqueous 
humour. The presence of the blood-aqueous barrier excludes large molecules 
from the aqueous humour. Small molecules such as urea and some amino 
acids enter the aqueous humour by diffusion from plasma. Serum proteins are 
present in the aqueous but at very low levels. The concentration of proteins in 
the aqueous humour varies with molecular size. They are mainly restricted to 
the smaller molecular weight proteins such as albumin and the beta-globulins. 
Glucose is found in the aqueous in slightly lower levels than in serum. Lactate, 
in contrast, is present at higher levels than in serum. Oxygen is present at a 
partial pressure of 55mmHg. The cation balance in aqueous humour is affected 
by the surrounding tissues. The major anions are chloride and bicarbonate. 
Organic constituents show a higher degree of variation from plasma 
concentrations. Steroid hormones and insulin are also present and enter into 
the aqueous by simple diffusion. However, prostaglandins, appear to be 
actively released into the aqueous by intraocular tissues such as the iris and
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possibly the trabecular meshwork. Cyclic AMP has been detected at a 
concentration about the same as in the serum. Other substances, such as 
hyaluronic acid, sialic acid, trivalent chromium ions, vitamin B \ 2  and 
monoamine metabolites have been found in the normal aqueous humour of 
various species.
Diffusion, aqueous flow, metabolism and interaction with surrounding 
tissues, make the composition of anterior chamber aqueous humour different 
from that of the posterior chamber aqueous humour. Most studies concerning 
the composition of the aqueous humour describe that which is obtained from 
the anterior chamber (Newell, 1986). Human studies often relate to fluid 
removed at the time of cataract extraction (Newell, 1986).
1.1.5 Function of aqueous humour
The secretion of aqueous humour generates the IOP required for an 
optically efficient globe. The flow of aqueous provides nutrition for the 
avascular ocular tissues that it bathes: the posterior cornea, trabecular
meshwork, crystalline lens and anterior vitreous. The constant flow of aqueous 
humour replenishes nutrients that have been taken up by the avascular tissues 
and carries away their metabolic waste products (Caprioli, 1992).
1.1.6 The blood-aqueous barrier (BAB)
The tight junctions (zonulae occludentes) between the NPE cells and 
between the non-leaky endothelial cells of the iris capillaries exclude large 
molecules from the aqueous. Together, they form the blood-aqueous barrier
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(anterior blood-ocular barrier), meaning that substances encounter difficulty in 
passing from the one fluid to the other.
A breakdown of the BAB may be brought about by a large variety of 
experimental and pathological conditions (Table 1), so that substances such as 
proteins, that are normally almost completely excluded from penetration, now 
appear in the aqueous humour in large amounts. By contrast, the 
concentrations of constituents that are secreted into the aqueous humour 
through an active transport mechanism and are found in much higher 
concentrations than in plasma (eg, ascorbate) will fall. This inflow of plasma­
like or 'plasmoid' aqueous or 'secondary aqueous' is responsible at least in part 
for the increased IOP that is found after paracentesis in rabbits (Al-Ghadyan, 
1979). Local synthesis and release of prostaglandins has been implicated in the 
irritative response after mechanical trauma to the eye which results in miosis, 
vasodilation and penetration of plasma protein into the aqueous humour which 
is usually, but not always, accompanied by a rise in IOP. The phase of acute 
ri§e in IOP usually gives way, after a short time, to a prolonged phase of 
lowered IOP (reactive hypotonia). Breakdown of the BAB occurs after 
intraocular surgery and may play an important role in the postoperative events 
that determine surgical outcome. The breakdown of the BAB is evidenced 
clinically by the presence of the so-called "flare". Disruption of the BAB has 
been reported in the contralateral eyes of patients who have had cataract 
extraction and lens implantation surgery (Miyake et al. 1984a, 1984b) and in 
the contralateral eyes of rabbits following anterior chamber paracentesis 
(Kottow and Seligman, 1978). Rabbit and clinical studies showed that residual 
viscoelastic materials can contribute to and/or augment the breakdown of BAB 
and/or interfere with barrier recovery following the trauma of surgery (Miyake
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and Mizuno, 1986; Machi et a l  1989; Tsurimaki and Shimizu, 1991a, 1991b).
TABLE 1: PROCEDURES PRODUCING A BREAKDOWN OF 
THE BLOOD-AQUEOUS BARRIER (Eakins, 1977)
Trauma
Mechanical injury to iris, lens
Contusions
Paracentesis
Chemical irritants 
Nitrogen mustard 
Formaldehyde 
Acid bums 
Alkali bums
Nervous activity 
Stimulation of trigeminal nerve
Endogenous mediators
Histamine
Bradykinin
Prostglandins
Serotonin
Acetylocholine
Miscellaneous 
Bacterial endotoxins 
X-ray irradiation 
Laser irradiation
Immunogenic mechanisms 
Bovine serum albumin
1.1.7 Aqueous humour outflow tisue anatomy
The aqueous humour flows from the posterior chamber through the pupil 
into the anterior chamber and leaves the primate eye by bulk flow via two 
pathways (conventional and unconventional) at the anterior chamber angle 
(Figure 5).
Total outflow of aqueous humour is the sum of the conventional flow 
through the trabecular meshwork (F ^ b )  and flow via the unconventional or 
uveoscleral route (U).
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1. Conventional aqueous outflow: In this pathway, aqueous humour leaves the 
eye through the trabecular meshwork, across the juxtacanalicular tissue into 
Schlemm's canal and from there into the collector channels and the aqueous 
veins and finally, to the episcleral veins and general venous circulation. The 
trabecular meshwork is sieve-like with many progressively smaller pores until 
Schlemm's canal is reached. Outflow is IOP-dependent through this pathway. 
Outflow can be summarized as follows:
Ftrab = (Pi-Pe)C
Where: Ftrab = trabecular outflow
Pj = intraocular pressure 
Pe = episcleral venous pressure 
C = facility of outflow
The Pe in a normal eye is about 8mmHg, making the pressure drop across the 
outflow tissues about 7mmHg assuming an average Pj of 15mmHg. Outflow 
facility in normal human eyes is approximately 0.3pl.min."lmmHg"l (Hart, 
1992).
2. Unconventional aqueous outflow: In this pathway, aqueous humour leaves 
the eye by traversing between ciliary muscle bundles and out to the 
suprachoroidal space where it is absorbed into the uveal circulation. 
Additionally, it is thought to leak through the sclera into the orbital tissue. 
This system is thought to be IOP-independent. In the monkey eye in vivo, it 
may account for as much as 70% of total outflow (Bill, 1971; 1977). In human
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Figure 5 The aqueous humour outflow pathways of the human eye.
Aqueous humour is secreted by the non-pigmented ciliary epithelium into the 
posterior chamber. It flows through the pupil into the anterior chamber and 
leaves the anterior chamber through the trabecular meshwork, which opens into 
the canal of Schlemm. In humans, about 20% of the aqueous humour leaves 
the eye through the suprachoroidal space and ciliary muscle spaces (the 
uveoscleral or unconventional route) (Newell, 1986).
eyes, estimates have ranged between 10% and 30% of total outflow depending 
on the age of the eye and the method of measurement (Bill and Phillips, 1971).
1.1.8 Intraocular pressure
Intraocular pressure (IOP) is the tissue pressure of the structures in the 
anterior chamber of the eye. In normal individuals it varies from a low of 
lOmmHg to a high of about 22mmHg with a mean of about 15mmHg (Hollows 
and Graham, 1966). The IOP is a dynamic parameter which oscillates with 
respiration and ocular pulse pressure (Newell, 1986). IOP follows a circadian 
rhythm being lowest at night and varies seasonally, being highest in winter 
(Vareilles et al, 1977; Bar-Elan, 1984), but there is little agreement amongst 
authors as to the times of peak or low pressure. IOP is increased in response to 
increased arterial and/or venous pressure in the head, such as that which 
occurs when the head is below the heart or with a Valsalva manoeuvre. It also 
rises on response to contraction of the extraocular muscles and to pressure on 
the eyelid. The basis for the average steady-state IOP is the inflow of aqueous 
humour from the ciliary processes and the resistance to outflow of aqueous 
humour through the drainage pathways. As derived mathematically, pressure is 
force per unit area. In Ophthalmic practice, the units are expressed as mmHg. 
IOP can be measured indirectly by tonometry (indentation or applanation) or 
directly by a pressure transducer connected to an intracameral cannula. In 
clinical practice, measurement of IOP is performed by applanation tonometry 
which measures IOP by subjecting the eye to a force that flattens the cornea. 
Two methods have been devised. In the first, the area of the cornea being 
applanated is held constant and a variable force is applied. In the second, the
13
force applied to the cornea is held constant and the area applanated varies. 
Goldmann applanation tonometry is the prime example of variable force 
applanation tonometry. It is based on the Imbert-Fick law (Goldmann and 
Schmidt, 1957), which states that the pressure within a sphere (P) is roughly 
equal to the external force (f) needed to flatten a portion of the sphere divided 
by the area (A) of the sphere which is flattened: P = f/A or PA = f.
1.1.9 Mathematical modelling of aqueous humour dynamics
In a physical system, flow (F) is defined as the volume (V) of fluid 
moving from one place to another in a unit o f time (T): F = V/T (Moses, 1987).
In the human eye the average rate o f flow is 2.5pl.min"l (Brubaker, 
1991). Under steady state conditions, the rate of aqueous flow into the eye 
(Fin) is equal to the rate of aqueous flow out of the eye (Fout):
Fin = Fout
Fluid flow always requires energy. In aqueous humour dynamics, the 
energy is supplied by hydraulic force, osmotic force and membrane pumps.
1. Hydraulic flow: Hydraulic flow is driven by a difference in tissue pressure 
across a barrier:
^hydraulic = C ( P l ’^2)
Where: F = flow
C = coefficient of facility of flow through the barrier (as
defined by Poiseuille's law)
Pl-P2 = the difference in tissue pressure of the
two sides of the barrier
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According to Poisseuille's law for streamline flow through a cylindrical tube:
C = 7tr4/nL 
Where: r = radius of the tube
n = fluid viscosity 
L = length of the tube 
C = coefficient of facility
In terms of fluid dynamics, the reciprocal of tissue coefficient o f facility 
of flow is resistance, or R. Therefore: R = 1/C and P 1-P2 = FR
The outflow of aqueous humour through the conventional route is driven 
primarily by hydraulic force. The resistance to aqueous outflow offered by the 
outflow pathway tissues results in a damming back of aqueous humour into the 
eye which stretches the cornea and sclera, building sufficient pressure to drive 
the aqueous humour through the outflow pathways. In terms of aqueous 
humour outflow, the smaller the pores in the aqueous outflow pathways, the 
higher the outflow resistance (or the lower the outflow facility). Further, 
because facility is proportional to the fourth power of the radius, a small 
decrease in the dimensions of the outflow pathways would result in a large 
decrease in outflow facility.
2. Osmotic flow: Osmotic flow is driven by hydrostatic pressure (generated 
by the solvent) and osmotic pressure (generated by dissolved materials) 
resulting from an unequal distribution of material across a membrane 
permeable to the solvent only. Where there is an osmotic pressure difference, 
solvent flow will continue from the low solute side to the high solute side until 
the pressure head across that barrier is zero. The pressure head is the
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difference in total pressure (osmotic + hydrostatic) on the two sides of the 
barrier.
3. Flow generated by metabolic pumps: Pumping of fluid across a
concentration gradient occurs across many of the body's epithelial barriers. In 
the ciliary processes, Na+/K+ ATPase releases the energy for many of the 
molecules transported into the aqueous humour.
1.1.10 Aqueous outflow physiology
1. Functional morphology of outflow tissues: The trabecular meshwork is 
thought to be the tissue offering the greatest amount of resistance to aqueous 
outflow, and is thought to be the site of the pathogenesis underlying the 
increased IOP in glaucoma. Much of what is known about the site of abnormal 
outflow resistance in glaucomatous and normal human eyes comes from early 
classic studies of Grant (1963). He measured outflow facility in enucleated 
eyes before and after an ab intemo trabeculotomy. He found that 
approximately 75% of the resistance to aqueous outflow was proximal to 
Schlemm's canal in normal eyes. Further, he found that enucleated eyes from 
individuals with glaucoma had a low outflow facility in vitro, and that the 
abnormal resistance to outflow was eliminated by removal of the trabecular 
meshwork.
The trabecular meshwork consists of three layers (Figures 6 and 7). The 
outermost layer is the cribriform layer (also referred to as the juxtacanalicular 
layer or the endothelial meshwork), which consists of several layers of
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endothelial cells embedded in extracellular matrix. The corneoscleral layer 
consists of a sieve-like matrix of equatorial plates covered by endothelial cells. 
The innermost layer, the uveal meshwork, consists of strands of loose 
connective tissue, each strand being lined by endothelial cells. Within the 
limbus, the drainage pathways consist of Schlemm’s canal, the internal 
collector channels and the aqueous veins, which typically carry only aqueous 
humour.
The ciliary muscle is involved in both conventional and unconventional 
aqueous outflow pathways. The longitudinal fibres, which are outermost, 
probably subserve changes in outflow facility when the ciliary muscle 
contracts. The reticular portion of the muscle consists of a large amount of 
connective tissue as well as muscle fibres. Its physiological function is not 
clear. The circular portion of the muscle subserves accommodation.
2. Aqueous outflow physiology: Much of our knowledge of drug effects on 
the outflow pathways has been derived from experimental anterior chamber 
perfusion of monkey eyes in vivo.
Outflow facility is typically measured by two-level constant pressure 
perfusion of the anterior chamber as originally described by Barany (1964). 
This involves placement of two needles into the anterior chamber; one 
connected to a perfusion reservoir and the other to a pressure transducer. The 
pressure in the eye is set by the height of the reservoir's meniscus at about 
2.5mmHg above the resting IOP in order to have a net flow of perfusion 
solution into the eye. After several minutes, the meniscus of the reservoir is 
raised again to effect an IOP of about lOmmHg higher. The pressure is 
alternated between these two levels throughout the measurement period.
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Outflow facility is calculated as:
Ctotal = (F2-F i)/(P2*P l)
Where: Q otal= total outflow facility
F i = measured flow from reservoir at P \
¥ 2  = measured flow from reservoir at ?2
Pj = 2.5mmHg above spontaneous IOP
P2 = 12.5mmHg above spontaneous IOP
Recently, an organ culture human eye preparation, suitable for outflow 
physiology studies has been introduced (Erickson-Lamy et ah 1991; Erickson- 
Lamy, 1992). In enucleated intact eyes or organ cultured anterior segments, 
outflow facility is measured at constant pressure after the method originally 
described by Grant (1963). Again, the anterior chamber is connected to a 
perfusion reservoir set at a given height above the limbus of the eye (typically 
equivalent to 10-15mmHg) and facility is measured as: C = F/P
3. The nature of aqueous outflow resistance: It is generally agreed that most 
of the resistance to aqueous outflow via the conventional route is located 
proximal to Schlemm's canal. However, there is controversy as to the exact 
site and nature of that resistance. Further, it is not completely understood 
exactly how aqueous humour crosses the endothelial lining of Schlemm's 
canal. A pressure/flow sensitive invagination-balooning of the inner wall 
cells has been observed; the so-called giant vacuoles (Johnstone and Grant, 
1973; Kayes, 1975; Grierson and Lee, 1975b; Tripathi, 1977; Johnstone, 
1979; Ainsworth and Lee, 1990). It is thought that aqueous humour leaves 
the anterior chamber through these vacuoles (Figure 8), however, a 
paracellular route may also exist.
18
SCLERA W IT H  
COLLECTOR CHA NNEL
SCHLEMM'S CANAL
---- -------------------------------------- IT m ------- v ----- **
3 ® g
-------------J
— -  V --------*  1*. — < “  ^
?
— "St "— * -------------r * ^ '----- - ' r f * — :— * -------r - ------ 1
ENDOTHELIAL M ESHW O RK
C O R N E O - SC L E R A L  
MESHWORK
UVEAL MESHWORK
Figure 6 Schematic representation of a section of the trabecular 
meshwork through chamber-angle tissue (Bill, 1975).
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Figure 7 Sagittal section through the chamber-angle and anterior 
portion of the human ciliary body (schematic drawing). Localisation of 
Schlemm’s canal and trabecular meshwork. A: non-filtering part of the 
meshwork; B: fdtering part of the meshwork; 1: cribriform  layer; 2: 
corneoscleral layer; 3: uveal layer (Rohen, 1986).
Figure 8 Light micrograph of the human trabecular wall of Schlemm's 
canal (SC) showing giant vacuoles (V) (Tripathi, 1977).
The lining cells are characterized by prominent bulging nuclei and vacuolar 
structures (v). Araldite section, x!306.
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With regard to the nature of outflow resistance, some investigators have 
hypothesised that the resistance is mediated by tight junctions between cells 
while other investigators have implicated the extracellular material in the 
juxtacanalicular meshwork as the site of resistance. There are experimental 
studies that support both views.
4. Influence of the ciliary muscle on trabecular outflow physiology: 
Contraction of the ciliary muscle mediates increased outflow facility as well as 
changes in accommodation. The ciliary muscle is highly innervated with 
cholinergic fibres and contracts in response to stimulation by muscarinic 
agonists. Although there was some thought that pilocarpine’s effect on outflow 
facility might be directly on the outflow pathway cells, experiments by 
Kaufman and Barany (1976) showed that the effect was mediated primarily by 
ciliary muscle contraction. Ciliary muscle contraction results in changes in the 
architecture of the conventional aqueous outflow pathway. However, whether 
and how these changes are involved in the effect on outflow facility is poorly 
understood.
5. Influence of the ciliary muscle on uveoscleral outflow physiology: The 
absence of a barrier between the trabecular beams and the ciliary muscle 
bundles results in a bulk fluid movement of aqueous humour into the spaces 
between ciliary muscle bundles and out into the suprachoroidal space. It has 
been shown that contraction of the ciliary muscle with cholinergic agents 
results in decreased uveoscleral outflow, due to an obliteration of the tissue 
spaces between ciliary muscle bundles (Bill and Walinder, 1966; Grierson et 
al, 1978). In contrast, chronic treatment with PGF2alpha> which lowers IOP,
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results in an increase in uveoscleral flow, which may be due to degradation of 
extracellular material in the spaces between the muscle bundles (Kaufman and 
Crawford 1989).
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1.2 HYALURONIC ACID AND HEALON
1.2.1 Introduction
Hyaluronic acid (HA), along with chondroitin sulphate, keratan sulphate, 
heparan sulphate and heparin are the major glycosaminoglycans (also known as 
mucopolysaccharides) which constitute the polysaccharide chains in 
proteoglycans. Proteoglycans consist of units made of polysaccharide (about 
95%) and protein (5%). These large polyanions bind water and cations and 
thereby form the extracellular medium or ground substance of connective 
tissue. Proteoglycans are important in determining the viscoelastic properties 
of joints and of other structures that are subject to mechanical deformation, 
acting as shock absorbers and structure stabilisers.
HA is synthesized in the cell membranes (Prehm, 1984) and is present in 
nearly all connective tissue matrices of vertebrate organisms. The highest 
concentrations of HA occur in synovial fluid, skin, vitreous body and certain 
specialised tissues such as umbilical cord and rooster comb. Levels of HA are 
also high during foetal development and in tissue repair and regeneration. 
Hyaluronate in the vitreous was discovered by Meyer and Palmer (1934). HA 
in the blood is present in a very low concentration (in human 0.015 - 
0.055pg.ml“l) originating mainly from the lymph, which in turn collects it 
from the connective tissue matrices (Engstrom-Laurent et a l  1985; Delpech et 
al, 1985). From the blood, HA is picked up by the liver and here metabolised 
lysosomal enzymes. The turnover of HA in the bloodstream is normally in the 
range of 0.3-1.0pg.min"VKg body weight (Laurent and Laurent, 1981; Fraser 
et a l  1983).
by
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Sodium hyaluronate is a very long molecule and its repeating 
disaccharide units consist of sodium D- glucuronate linked to an N-acetyl-D- 
glucosamine molecule by a b 1-^4 glucoside bond. The two disaccharide 
units are linked together with b l->3 glucoside bonds forming the 
tetrasaccharide segment of a long, unbranched chain (Figure 9).
CH.OH
,0HHO
HO"HO
HO•OH HNCOCHj
'CH2OH
J  v .V .
N-Acety l-D-G lucosamine Na-D-Glucuronote
Figure 9 The tetrasaccharide segment of a sodium hyaluronate chain.
A 4 million molecular weight hyaluronate molecule contains 
approximately 10000 disaccharide units and has a length of 10m (Bothner and 
Wik, 1987). This long polysaccharide chain has not been shown to contain any 
covalently bound proteins, peptides, amino acids, other sugar molecules or 
nucleic acids. Nor is there any evidence of branching or of permanent 
crosslinks between the individual chains. Most important, the long 
polysaccharide chain is stabilised by hydrogen bonds and water bridges formed 
between adjacent individual sugar molecules and between neighbouring chains. 
X-ray diffraction studies of hydrated sodium hyaluronate membranes and 
sheets indicate ordered structures associating two molecular coils into a soluble
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helical structure. The long molecular chain forming a random, kinked coil 
configuration constitute the basis of the specific viscoelastic properties of the 
molecules in a physiological ionic environment (Dea et al. 1973; Amott et a l 
1983). HA molecules in water or in physiological salt solution occupy a large 
molecular domain. This sponge-like molecule contains much water. The 
hydrated specific volume of a sodium hyaluronate molecule in physiological 
salt solution is 2000-6000ml per gram. This means that when a solution 
contains 0.16-0.5mg sodium hyaluronate per ml solvent (0.016-0.05% 
solution), all the solvent space is occupied (Balazs, 1986). The unique 
rheological properties of the hyaluronate molecule stem from its large 
molecular volume and from the extensive interaction and entanglement of the 
molecular coils (Gibbs etal, 1968; Comper and Laurent, 1978).
The property of viscoelasticity is the essence of usefulness of the 
viscoelastic materials. Viscosity is a measure of a solution's resistance to 
flow. It is dependent on the solution's degree of movement, also known as the 
shear rate. To facilitate optimal intraocular manipulations, a high viscosity at 
low shear rates (for space maintenance and tissue protection), a moderate 
viscosity at medium shear rates (allowing instrumentation and implantation) 
and a low viscosity at high shear rates (allowing injection via a cannula) is 
desired. The decrease of viscosity with increasing shear rate is also referred to 
as pseudoplasticity (shear thinning behaviour). The viscosity of a solution can 
be increased by increasing either the concentration or the molecular weight of 
the solute (Bothner and Wik, 1987, 1989). Viscosity is complemented by the 
property of elasticity, a measure of the capacity of a solution to resist 
deformation. When energy is transmitted to a viscoelastic solution at a low 
frequency or slow impact, the solution reacts primarily as a viscous compound.
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However, when energy is transmitted at a high frequency or fast impact, the 
solution reacts as an elastic compound or gel. This allows a viscoelastic to be 
introduced into the eye via a 27 or 30 gauge cannula and yet maintain the 
intraocular space in which it is placed even in the face of an open incision. On 
the molecular level, this means that under low frequencies, the polysaccharide 
coils slip by each other and conformation and configuration rearrangement 
results in viscous flow. At high strain frequencies, this rearrangement cannot 
occur. Under these conditions, the molecular chains deform and mechanical 
energy is stored as elasticity. Thus, it acts as a reversible mechanical energy- 
storing and energy-dissipating system (Pruett et ah 1979). The degree of 
elasticity increases with increasing molecular weight of an elastic compound
(Larson etaL 1989).
1.2.2 Hyaluronic acid in the anterior chamber of the eye
In the eye, HA is found not only in the vitreous, but also at a much lower 
concentration in the aqueous humour and in the connective tissue of the 
anterior chamber angle. HA was detected in the aqueous humour over 50 years 
ago (Meyer and Smyth, 1938). The concentration of HA in the aqueous 
humour is about l-3pg.ml"l; about 1% of that in the vitreous (Laurent, 1981; 
1983).
The source of HA found in the aqueous humour is not entirely clear. 
Some authors state that the majority of it derives from the vitreous cavity and 
only a small amount from the corneal endothelium, which is covered by a thin 
layer of HA, and where hyaluronate-binding sites have been found (Madsen et 
al, 1989; Harfstrand et a l  1992). However, other studies suggest that the
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majority of hyaluronate derives from local sources (ie, ciliary body). Detailed 
studies in rabbit and cattle have shown that in both species, HA is 
polydispersed; ie, it shows a broad range of molecular weight values (Laurent 
and Granath, 1983). HA found in the rabbit aqueous humour has an average 
molecular weight higher than that of vitreous; moreover, the turnover of HA in 
the vitreous is only 15% of that in the aqueous, the latter being estimated as 
3 pg/day (Laurent and Fraser, 1983). These findings imply that in the rabbit 
aqueous humour HA is not a simple degradation product of vitreous HA; some 
or possibly most of it probably originates from the anterior segment of the eye. 
In adult cattle as in rabbit a large proportion of the HA in the aqueous humour 
is of higher molecular weight than that of the vitreous (Laurent and Granath, 
1983). However, unlike rabbit, cattle aqueous contains HA of lower molecular 
weight that could have originated from the vitreous by diffusion. Studies using 
explants of human and monkey ciliary body as well as carefully dissected tips 
of the ciliary processes support the view that these tissues may secrete HA into 
the aqueous humour (Rohen et al 1984, Schachtschabel et al 1984).
1.2.3 Hyaluronic acid and the trabecular meshwork
The major chemical components of the human trabecular meshwork (TM) 
are type I collagen and elastin fibres. In addition, basement membrane-like 
structures consisting in part of type IV collagen have been identified in human 
TM (Rodrigues et a l  1980). The TM is rich in glycosaminoglycans (GAGs) 
and also contains fibronectin and laminin (Mizokami, 1977; Rodrigues et ak 
1980; Polansky et ak 1984; Sramek et ak 1987). GAGs are localised on the 
surface of the TM cells and Schlemm's canal and are in close association with
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the connective tissue elements and extracellular spaces of the TM. 
Histochemical studies, mainly using alcian blue or colloidal iron, combined 
with electron microscopy, have demonstrated a broad spectrum of GAGs in the 
TM in a variety of animal species and in humans, with HA appearing as the 
most abundant species in human TM (Zimmerman, 1957; Armaly and Wang, 
1975; Grierson and Lee, 1975a; Mizokami, 1977; Knepper et al 1981; Acott et 
al, 1985).
Many years ago, Bar any (Bar any 1953/54, 1956; Bar any and Woodin, 
1955) showed that perfusion of the aqueous outflow system with hyaluronidase 
resulted in an increase in outflow facility. Studies on hyaluronidase-infused 
rabbit eyes suggest that HA is an important component of the aqueous outflow 
resistance (Knepper et al. 1984). This was shown by comparing the effect of 
testicular hyaluronidase (which partially degrades not only hyaluronate but also 
chondroitin sulphate and possibly dermatan sulphate) with HA lyase (which 
degrades only HA specifically and completely). The latter was found to be 
more effective than testicular hyaluronidase in degrading HA of the TM and in 
reducing aqueous outflow resistance. HA lyase has a wider pH range than 
testicular hyaluronidase and at physiological pH completely removes all of the 
HA without affecting other GAGs present in the TM. These findings suggest 
that HA, more than other GAGs, may play a role in controlling outflow 
facility.
Hyaluronidase has not been detected in native aqueous humour. 
However, there is some indirect evidence for hyaluronate-degrading activity in 
surrounding ocular tissues. HA was injected into the anterior chamber of 
rabbits and the HA content of the iris-ciliary body reached a high level after 2h 
but returned to normal level within 24h (Miyauchi and Iwata, 1984). This
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rapid elimination was attributed to enzymatic breakdown after diffusion into 
the iris-ciliary body and the angular aqueous plexus/sinus.
The concentrations of HA in glaucomatous individuals were found to be 
normal, (Laurent, 1983) observations that cast some doubt on the commonly 
held view that a hyaluronidase sensitive material in the aqueous may be one of 
the causes of impaired outflow facility in glaucoma. This would not, however, 
exclude a possible accumulation of HA or other GAGs in the TM, not 
necessarily originating from the aqueous, as a factor in impaired outflow 
facility.
1.2.4 The non-inflammatory fraction of sodium hyaluronate and the 
development of Healon
In 1972, Balazs et al suggested the use of sodium hyaluronate, which is a 
natural viscous material, as a vitreous substitute for posterior segment ocular 
surgery, but unexpected problems soon emerged. It turned out that although 
highly purified, sodium hyaluronate contained an inflammatory component 
which caused a characteristic invasion of mononuclear cells (mainly 
macrophages) when injected into tissue compartments (Balazs, 1986, 1989). 
The infiltration of mononuclear cells was accompanied by an increased protein 
concentration that reached a maximum 48h after injection.
The vitreous cavity of the primate eye proved to be especially sensitive to 
this inflammatory reaction. It took several years to develop the necessary 
reproducible and reliable techniques to prepare the so-called non­
inflammatory fraction of sodium hyaluronate (NIF-SH).
In 1976, the NIF-SH extracted from such tissues as umbilical cords and
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rooster combs was isolated and assayed in the primate eye. This preparation 
neither caused ocular inflammation even after multiple injections, nor did it 
potentiate the inflammatory reaction induced by other known inflammatory 
agents. This NIF-SH fraction was first manufactured by Biotrics, Inc. 
(Arlington, MA) and later by Pharmacia AB (Uppsala, Sweden), and is 
currently marketed by Kabi Pharmacia Ophthalmics AB (Uppsala, Sweden) 
under the trade name Healon in disposable syringes containing 0.5ml of 1% 
sodium hyaluroante in aqueous buffer. Healon is registered in some countries 
as Healonid. Healon contains 10±lmg.ml"l NIF-SH dissolved in a sterile, 
preservative-free phosphate buffer (0.146M NaCl, 0.34mM NaH2P0 4 , 1.5mM 
Na2HPC>4; pH 7.2 ± 0.2). The molecular weight of Healon is 2-4 x 10^ , its 
viscosity 100-300 x 10^ centistokes and its colloid-osmotic pressure 9mmHg. 
The concentration of impurities such as proteins (as amino acids), nucleic acids 
and sulphated GAGs in the solution is very small; less than 0.005mg.ml- l, 
0.03mg.ml“l and 0.03mg.ml"l, respectively.
The introduction of Healon has given birth to the concept of viscosurgery. 
The term viscosurgery was coined by Balazs to describe surgical procedures 
which employ viscoelastic solutions to produce certain surgical effects. In 
ocular surgery, viscosurgery is used to protect eye tissues from mechanical 
trauma, to create and maintain tissue space for surgery and to permit the 
manipulation of tissues without mechanical damage.
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1.2.5 Turnover of hyaluronate and the non-inflammatory fraction of 
sodium hyaluronate in the eye
The half-life time of NIF-SH in the anterior chamber depends on the 
viscosity of the solution and the amount injected (Denlinger and Balazs, 1988).
The more NIF-SH injected and the greater the viscosity of the injected 
solution, the more time is required for the NIF-SH molecules to clear the 
anterior chamber. In one study (Schubert et al. 1981), 6 samples of 1% NIF- 
SH of differing viscosities (ranging from 10 to 940 x 10^ centistokes) were 
injected into the owl-monkey eye in two volumes replacing approximately 50% 
and 75% of the volume of the anterior chamber (0.22 and 0.35ml, 
respectively). With the smaller volume, the rate of disappearance depended 
entirely on the viscosity, with the highest viscosity solution cleared | from the anterior 
chamber with a rate of 50gl/h and the lowest viscosity cleared the eye with a 
rate of 120pl/h. When the larger volume of the aqueous humour was replaced, 
the initial rates of disappearance were much slower; the lowest viscosity and 
highest viscosity samples cleared the anterior chamber at rates of 30 and 
70pl/h, respectively. These experiments showed that 24h after the injection 
only 27% ofjthe high viscosity-low volume solution remained compared with 
50% of the high viscosity-high volume solution. By 48h all solutions except 
for the high viscosity-high volume solution had cleared from the eye. By 72h 
15% of the high viscosity-high volume solution still remained in the anterior 
chamber. In these experiments, the molecular size of the hyaluronate within 
the anterior chamber did not change. Therefore, there appears to be no 
endogenous capacity for degradation. It is interesting to note that the maximal 
increase in IOP in all cases occurred during the first 7h and returned to normal
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24h after injection, a time at which as much as 370 times the normal 
concentration of hyaluronate still remained in the anterior chamber.
Fraser et al (1981), Laurent and Fraser (1983) and Laurent et al (1988) 
studied the disappearance of hyaluronate from the rabbit eye with labelled 
polysaccharides. They found that when hyaluronate is injected into the 
vitreous it leaves the tissue by diffusion and that the disappearance rate is 
molecular weight dependent. They also found that endogenous hyaluronate in 
the vitreous has a half-life of about 70 days similar to that in humans. Trace 
amounts of hyaluronate injected into the anterior chamber are transported by 
aqueous flow into the general circulation and have a half-life of 60-80 min in 
the eye. When concentrated sodium hyaluronate (1%) was injected into the 
anterior chamber, the disappearance rate was slower. When 0.05 or 0.2ml was 
injected, initial disappearance rates corresponding to half-lives of 9 and 14h, 
respectively, were recorded. The rate accelerated, however, as the substance 
disappeared from the eye.
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1.3 CATARACT SURGERY AND HEALON
1.3.1 Lens and cataract
The crystalline lens is a transparent biconvex structure, located directly 
behind the iris and pupil and anterior to a shallow depression in the vitreous 
face, the lenticular fossa. It is approximately 10mm in diameter and 4mm thick 
(Newell, 1986). It is held in position by its suspensory ligament (zonule) 
which connects the lens to the ciliary body. The zonule is composed of fine 
fibrils of modified collagenous tissue on the outer surface of the lens capsule. 
The zonules attach to the lamellar portion of the lens capsule on either side of 
the equator and to the basement membrane of the ciliary epithelium in the 
valleys between the ciliary processes. The ciliary attachment is long and fibres 
may extend to the pars plana of the ciliary body. Other fibres attach to the 
anterior vitreous face. The insertions extend about 2mm in front and 1mm 
behind the lens equator. The lens is composed of (1) a lens capsule that 
envelopes the entire lens, (2) an anterior lens epithelium located immediately 
beneath the anterior lens capsule and (3) a lens substance consisting of the 
cortex (newly formed lens fibres with nuclei) and the nucleus (a dense central 
area of fibres that have lost their nuclei).
The lens capsule is a smooth, homogenous, acellular structure. The 
anterior capsule is the basement membrane of the anterior lens epithelium and 
is the thickest basement membrane in the body. The posterior capsule is the 
basement membrane of lens cells (fibres). The lens substance consists of 
elongated lens fibres. Young lens fibres form at the equator and migrate 
towards the anterior of the lens. They contain nuclei and are attached to their
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basement membrane, the posterior capsule. Mature lens fibres have lost their 
nuclei and are no longer in contact with the posterior capsule. These form 
most of the substance of the lens. They are packed into an increasingly dense, 
central nucleus. The lens fibre proteins are composed of a water-soluble 
fraction, the crystallins, and a water-insoluble group.
The term cataract is used to describe the condition of opacification of the 
crystalline lens of the eye. Age- related (senile) cataract is the commonest 
form of cataract and appears to be an accentuation of normal ageing changes 
which occur in the lens though, occasionally, it is seen as early as 40 years of 
age. It is divided into two main types: a senile opacification of the nucleus of 
the lens and a senile opacification of the cortex. A large number of senile 
cataracts possess both nuclear and cortical opacities. Age-related cataract is 
the main cause of blindness and visual impairment throughout the world (Leske 
and Sperduto, 1983; Kupfer, 1984; Foster and Johnson, 1990). With the 
ageing of the population, the overall prevalence of visual loss due to lens 
opacities continues to increase every year. More than 17 million persons 
worldwide are estimated to be blind from cataract (Foster and Johnston, 1990). 
Surgical removal is the only treatment for cataract and cataract extraction is the 
single most common intraocular surgical procedure.
Extraction of age-related cataract may be performed in two ways: by 
removal of the entire lens (by cryoextraction), including its capsule 
(intracapsular cataract extraction; ICCE) or by excision of a portion of the 
anterior capsule followed by expression of the nucleus and cortical clean-up 
with retention of the posterior capsule (extracapsular cataract extraction; 
ECCE). Phacoemulsification is a type of ECCE in which the lens matter is 
broken up by ultrasonic vibration into an emulsion which can then be aspirated
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from within the capsular bag and replaced with infusion fluid. The ICCE was 
the method of choice until early 1980s. Since then, ECCE has become 
increasingly more popular because of the use of posterior chamber intraocular 
lenses (p/c IOL) that require an intact equatorial lens capsule for support. In 
ECCE, the IOL, with its haptics, is inserted into the ciliary sulcus (a groove 
between the root of the iris and the ciliary body) or into the capsular bag. The 
latter is known as endocapsular or envelope-like technique.
1.3.2 Cataract surgery and corneal endothelial cell damage
Corneal clarity is dependent on the endothelium which serves as a barrier 
and physiological pump in maintaining stromal dehydration. Injury to comeal 
endothelial cells is a risk in cataract surgery, particularly when cataract 
removal is combined with IOL implantation. Endothelial damage may occur at 
any stage in even routine procedures in the course of any type of cataract 
surgery from the opening of the anterior chamber with manipulation of the 
cornea to insertion of an IOL following cataract extraction.
In most instances of cataract surgery-induced damage, a transient 
insufficiency of endothelial function results causing striate keratopathy 
(comeal decompensation) which in some instances may cause permanent visual 
dysfunction. Additional trauma to the endothelium due to IOL implantation is 
likely to compromise the endothelium further. Comeal endothelial cells do not 
regenerate through mitosis. Therefore, damage to cells during anterior segment 
surgery, resulting in a loss of endothelial cell density, is thought to be a major 
factor in postoperative comeal oedema. Bourne and Kaufman (1976) reported 
a 62% decrease in endothelial cell density following IOL implantation. This
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damage is thought to have resulted from contact between the cells and the 
surface of the implant and varies with the style of the implant used (Kaufman 
and Katz, 1976). When cells are lost, the denuded area is covered by 
enlargement and sliding of remaining cells resulting in a net decrease in cell 
density (Khodadoust and Green, 1976). It is thought the function of the 
endothelium as a whole is compromised by the decreased cell density. Early 
attempts to avoid surgically-induced endothelial cell damage involved the 
filling of the anterior chamber with air, balanced salt solution, or Hartmann's 
solution to buffer the endothelium against trauma. These attempts resulted in 
limited success, as the air and solutions were lost as the cornea was retracted.
1.3.3 Viscoelastic materials and cataract surgery
Endothelial dystrophy following cataract surgery has almost become a 
preventable complication since the advent of endothelial specular microscopy 
in the late 1970s. This technological advance contributed greatly to the 
knowledge of age and disease-related changes in the density of corneal 
endothelial cells. Careful studies have shown which procedures and 
techniques result in the least traumatic loss of endothelial cells. Methods of 
cataract removal and styles of IOL have changed because of these findings 
(Hoffer, 1979, 1982). Since the recognition by Bourne and Kaufman (1976) 
and Forstot et al (1977) that corneal endothelial cell loss is greater after 
cataract extraction and IOL implantation than after cataract extraction alone 
and that contact between the IOL and the endothelium at the time of surgery is 
a major factor in endothelial damage (Kaufman and Katz, 1976), several 
substances have been investigated for their protective effect. The rationale
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behind the use of these substances has been to prevent contact between the IOL 
and the corneal endothelium by maintaining the anterior chamber shape and to 
prevent endothelial damage by coating the IOL or the endothelium or both, 
should contact occur. The literature describes the average endothelial cell loss 
in the hands of experienced surgeons in the 1970s to be about 50% (Forstot et 
al, 1977; Binkhorst et al. 1978; Sugar et al. 1978; Binkhorst, 1980). The 
substances that have been investigated to various extents in animal and human 
eyes include balanced salt solution (BSS), air, plasma, serum, albumin, gamma 
globulin, TC I99, polyvinylpyrrolidone, methylcellulose, chondroitin sulphate 
and sodium hyaluronate (Kirk et al, 1977; Bourne et al, 1979; Soli et ak 1980; 
Fechner and Fechner, 1983; MacRae et al, 1983; Aron-Rosa et al. 1983; 
Fechner, 1985; Rosen et al. 1986). Of these substances, sodium hyaluronate 
was the first one introduced commercially and is the most widely used.
Healon was first used in anterior segment surgery animal lens implant 
experiments by Miller et al (1977) and was later successfully used in human 
cataract surgery (Graue et al, 1980; Miller and Stegmann, 1980; Pape and 
Balazs, 1980). Healon reduced postoperative corneal endothelial swelling and 
cell loss when it was used during cataract surgery. Its clinical use has resulted 
in reported endothelial cell loss of only 9.7% to 18% (Miller and Stegmann, 
1980, 1981, 1982; Pape, 1980; Lazenby and Broocker, 1981; Percival, 1983).
However, not all reports have shown a significant protective effect of 
Healon. Hoffer (1982) and Bourne et al (1984) were unable to demonstrate 
significant decreases in postoperative endothelial cell loss with the use of 
Healon during ECCE with p/c IOL. These authors suggested that the 
protective effects of Healon might be more demonstrable in operations 
normally accompanied by greater cell loss or unusually traumatic surgery.
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Some of the many uses of viscoelastic substances during cataract surgery 
as reviewed by Liesegang (1990) are shown in Table 2 and have been 
described in detail by many authors (Miller et al, 1977; Pape, 1980; Pape and 
Balazs, 1980; Percival, 1981; Hoopes, 1982; Stegmann and Miller, 1982; 
Holmberg and Philipson 1984a, 1984b; Polack, 1986, Larson et a l  1989). A 
number of viscoelastic substances are currently available for use in intraocular 
surgery (Table 3) and several new preparations are in various stages of 
development. Healon was the first viscoelastic substance introduced 
commercially and is the standard against which newer viscoelastic substances 
are compared. Apart from cataract surgery and vitreoretinal surgery, 
viscoelastics are used in penetrating keratoplasty (Polack, 1981; Steele, 1983), 
glaucoma surgery (Hung, 1985; Raitta and Setala, 1986), anterior segment 
reconstruction (Roper-Hall, 1983; Drews, 1986), plastic surgery (Lemer and 
Boynton, 1985), eye muscle surgery (Clorfeine and Parker, 1987) and tear 
dysfunction states (Limberg et al, 1987). It is estimated that viscoelastics are 
used in about 60% of all ophthalmic procedures and about 75% of all cataract 
extraction procedures.
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TABLE 2: USES OF VISCOELASTIC MATERIALS IN CATARACT 
SURGERY
In extracapsular cataract extraction
- Cushion anterior chamber
- Fill, maintain and restore the depth of the anterior 
chamber
- Coat and protect comeal endothelial cells
- Secure anterior chamber with vitreous pressure
- Push back choroidal haemorrhage
- Prevent scrolling of the anterior capsule of the lens
- Break of posterior or anterior synechia
- Hydraulic separation of nucleus and cortex
- Maintain mydriasis
- Tamponade bleeding vessels on iris or in wound
- Restore globe integrity when vitreous is lost
- Ease evacuation of nucleus by injection under capsule
- Help better wound adaptation with fully constituted 
globe
- Help reposition of detached Descemet's membrane
- Protect cornea by acting as epithelial wetting agent
- Ease passage of limbal sutures
In IOL insertion
- Expand capsular bag or ciliary sulcus for insertion of 
the implant
- Coat intraocular lens
- Tamponade break in posterior capsule and push back 
vitreous for placement of implant
In phacoemulsificaton
- Coat comeal endothelium to protect from eddy currents 
of irrigating fluids or whirling lens particles
- Cushion introduction of various large instruments 
through small opening
- Push iris - vitreous or iris - capsule diaphragm back 
and maintain deep anterior chamber
- Help rotate nucleus within capsular bag
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In intracapsular cataract extraction
- Protect the corneal endothelium from heat and exposure 
drying, as well as from the effects of cryoextraction
- Coat and protect comeal endothelium from potentially 
sliding contact between the lens and the cornea
- Help for manipulating the iris diaphragm in 
postextraction vitreous/iris bulge
- Restore and maintain the anterior chamber depth during 
wound closure
- Help for localising bleeding from a peripheral 
iridectomy and haemostasis
- Prevent fluid vitreous from having access to the wound 
area and thereby its incarceration
- Reform the posterior chamber and therefore create the 
space into which a retropupillary intraocular lens will 
be inserted with consequential protection of the 
anterior hyaloid membrane
- Deepen the anterior chamber angle to facilitate 
placement of the loops of an anterior chamber 
intraocular lens.
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TABLE 3: COMMERCIAL VISCOELASTIC PREPARATIONS
Concen-
Viscoelastic tration
Preparation material (mg.ml“l)  Manufacturer
Healon Sodium hyaluronate 10 Pharmacia
Am Vise Sodium hyaluronate 10 IOLAB
AmVisc Plus Sodium hyaluronate 16 IOLAB
Viscoat Sodium hyaluronate 
Chondroitin sulfate
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Alcon
Occucoat Hydroxyl-
methylcellulose 20 Storz
1.3.4 Complications of Healon
Although Healon is a useful surgical tool, besides its high cost, there are 
disadvantages and complications resulting from its use. Healon is a highly 
viscous clear solution at rest very similar to the vitreous and is therefore 
difficult to identify when both are present in the anterior chamber. If Healon is 
left inside the eye, inflammatory cells, red blood cells and lens material may 
remain suspended in the anterior chamber, giving the appearance of a 'plastic' 
anterior uveitis (Larson et al. 1989). This may delay the reabsorption of these
materials and cause persistent inflammation. Sodium hyaluronate contained in
Healon is extracted from avian tissues and despite vigorous purification
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procedures, minute amounts of protein are present. Although immunogenicity 
studies in both animals and humans showed no evidence of immunological 
reactions (Richter, 1979; Richter et al. 1979), the possibility of idiosyncratic 
reaction following its use remains (Hultsch, 1980).
Potential endothelial cellular toxicity is another disadvantage of Healon. 
Although Healon does not decrease corneal wound strength (Arzeno and Miller, 
1982), some reports suggest that it may have toxic effects on the corneal 
endothelium (Meyer and McCulley, 1989; Slack and Hyndiuk, 1994).
The most serious complication of the use of Healon is the induction of 
early (<24h) postoperative intraocular hypertension over and above that 
reported following cataract surgery before its advent (Rich et al, 1974; Haimann 
and Phelps, 1981; Tuberville et a l  1983). This augmentation and prolongation 
of the IOP elevation may occur especially if the Healon is left within the eye 
postoperatively. This has been referred to as Healon-block glaucoma (Hoffer, 
1982).
The role of Healon as a cause of postoperative intraocular hypertension 
has been controversial. The original reports on the use of Healon did not 
mention any postoperative IOP rise. In several studies no statistically significant 
differences in IOP were observed after use of Healon compared with controls 
(Pape and Balazs, 1980; Miller and Stegmann, 1981; Stegmann and Miller, 
1982; Holmberg and Philipson, 1984a, 1984b). However, other studies showed 
significant rises in IOP and advocated aspiration or dilution of Healon at the 
end of surgery (Pape, 1980; Lazenby and Broocker, 1981; Olivius and 
Thorbum, 1985) . The discrepancies in results may be due to differences in 
surgical technique (ECCE or ICCE, and whether or not the viscoelastic was 
removed at the end of surgery) and in the postoperative times that the pressures
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were monitored. Most clinicians record the first postoperative IOP 
measurement after about 24h (1st postoperative day) and the early postoperative 
IOP rise passes, in most cases, unnoticed. In a prospective randomized 
investigation of postoperative IOP in patients undergoing ICCE with or without 
Healon, Passo et al (1985) found that the maximal difference in IOP between 
the Healon group and the control group occurred approximately 16h 
postoperatively. Cherfan et al (1983) emphasized the importance of early 
postoperative measurements when evaluating the effect of Healon on 
postoperative IOP and stated that IOP measurements made one day 
postoperatively were insufficient. Collectively, the IOP readings in studies 
which did not show increased IOP were taken 24h or more after surgery. The 
presence of increased IOP more than 24h after cataract surgery may be a 
consequence of excessive surgical trauma or a compromised trabecular 
meshwork (Liesegang, 1990).
1.3.5 Methods to reduce Healon-induced postoperative intraocular
pressure elevation
A number of investigators have advocated methods to attenuate the 
Healon-induced IOP increases. Some authors have reported successful 
attenuation of the rise in IOP by prophylactic treatment with beta blockers, 
acetazolamide and/or miotics (Miller and Stegmann, 1981, 1982; Percival, 
1982; Lewen and Insler, 1985; Anmarkrud et a l 1992). However, the use of 
pre- or postoperative anti- glaucoma remedies is often ineffective and/or slow 
to take effect. There is no consensus that pre- or postoperative therapy with 
acetazolamide, miotics or beta-adrenergic antagonists prevent the postoperative
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IOP pressure elevation induced by viscoelastics (Krupin et al. 1989).
The practice of diluting or removing Healon from the anterior chamber to 
prevent postoperative increases in IOP has been recommended by many authors 
(Pape, 1980; Lazenby and Broocker, 1981; Miller and Stegmenn, 1981, 1982; 
Hoffer, 1982; Stegmann and Miller, 1982; Cherfan et al, 1983; Glasser et al, 
1986). Pape (1980) reported higher mean IOP values one day postoperatively 
in non- irrigated eyes than in irrigated eyes (38.3 and 19.4mmHg, respectively). 
Cherfan et al (1983) found that using a minimal quantity of Healon and diluting 
it with BSS at the end of surgery lessened but did not prevent postoperative 
increases in IOP. Olivius and Thorbum (1985) measured IOP following ECCE 
and IOL implantation, with and without irrigation of Healon at the end of the 
surgery. When Healon was left in the eye, 35% of the patients had an IOP 
increase of greater than or equal to 20mmHg during the initial ten hours, 
compared with 11% of the group in which Healon was washed out. Twenty 
hours after surgery, the irrigated eyes had a lower mean IOP than the non­
irrigated eyes (15.6mmHg vs 23.8mmHg). Glasser et al (1986) reported that the 
IOP elevations peaked within 4h after instillation of Healon and were 
significantly reduced by anterior chamber washout. However, although 
irrigation appears to attenuate the IOP increase, substantial increases in IOP can 
still occur postoperatively. Bourne et al (1984) aspirated Healon at the end of 
surgery but still observed a significant rise in IOP in the 1st postoperative day 
compared with the preoperative value. Similarly, Naeser et al (1986) found that 
in spite of aspiration of Healon, a significant rise in IOP was observed after 6h 
both in comparison with the preoperative values and with controls. Anmarkrud 
et al (1992) studied the effect of Healon on the acute IOP rise after ECCE with 
p/c IOL and found a significant rise in IOP at 3-6h postoperatively, whether or
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not Healon was aspirated.
It is clear that the success of the present attempts to attenuate Healon- 
induced IOP rises either by anti-glaucoma drugs or by irrigating/aspirating 
Healon at the end of surgery is at best limited.
1.3.6 Mechanism of Healon-induced intraocular pressure elevation
The mechanism underlying Healon-induced increases in IOP probably 
involves an obstruction of aqueous outflow through the conventional outflow 
routes. Support for this hypothesis comes from clinical as well as laboratory 
data. The relative lack of success of acetazolamide in significantly preventing 
the Healon-induced rise in IOP supports the hypothesis that Healon causes a 
transient but massive obstruction of the trabecular meshwork rather than 
increased production of aqueous humour. The observation that the Healon- 
induced increase in IOP occurs quickly and is short-lived (i.e. <24h) further 
supports the hypothesis that the trabecular meshwork is obstructed with 
fragments of hyaluronate or with small accumulations of undiluted hyaluronate. 
These clinical observations are supported by laboratory findings. Berson et al 
(1983) found a 65% decrease in outflow facility one hour after the instillation 
of sodium hyaluronate into the anterior chamber of enucleated human eyes 
compared with a 32% decrease when the hyaluronate was immediately irrigated 
from the anterior chamber. However, after three hours outflow facility showed 
a further overall decrease to 60%. They concluded that irrigating the anterior 
chamber after using sodium hyaluronate does not eliminate the possibility of 
severe postoperative glaucoma (i.e. anterior chamber washout delayed but did 
not prevent the reduction in outflow facility).
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It is not clear whether obstruction of the outflow pathways occurs because 
of the high viscosity of the Healon solution or because of the high molecular 
weight (and size) of the polymers. If the egress of Healon from the anterior 
chamber is viscosity-dependent as is thought by Pape (1980), substances with 
higher viscosity would theoretically have greater difficulty leaving the anterior 
chamber and consequently cause greater increase in IOP. However, Schubert et 
aj (1984) found that low viscosity solutions of NIF-SH caused a greater and 
more prolonged increase in IOP in the owl monkey than high viscosity solutions 
of NIF-SH. Levy and Boone (1989) suggested that the viscosity of the 
hyaluronate solution can be increased while the likelihood of IOP elevation can 
be reduced by using lower molecular weight hyaluronate molecules. In the 
rabbit eye, instillation of sodium hyaluronate decreased outflow facility, but a 
mixture of hyaluronate and hyaluronidase produced no significant change in 
outflow facility (Hein et al. 1986). Other rabbit studies found that IOP 
increased with sodium hyaluronate and that the recovery time to normal 
pressure was not dependent on molecular weight or concentration of sodium 
hyaluronate (Iwata et al, 1984). However, the recovery times of protein and 
ascorbate concentration to normal levels were longer than those obtained after 
injection of lower molecular weight and lower concentrations of sodium 
hyaluronate. A rapid recovery of the aqueous humour components to normal 
levels is presumably desirable after anterior segment surgery because the 
constituents of aqueous humour are necessary to maintain good conditions for 
the metabolism of the anterior segment tissues.
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1.3.7 The use of Healon in compromised eyes
Routinely performed cataract surgery often causes ocular hypertension in 
the first hours after surgery (Rich et al. 1974; Haimann and Phelps, 1981; 
Tuberville et a l  1983). The elevations of IOP after cataract surgery are 
miltifactorial and may be due to debris, residual lens material, products of 
inflammation, prostaglandin release, inflammatory cells, red blood cells, 
breakdown of the blood-aqueous barrier, suture-induced changes in the 
trabecular meshwork or watertight wound closure. The immediate effect of 
cataract extraction on IOP continues to generate conflicting reports from a 
reduction or little change to universal elevation. However, there is reasonable 
agreement that the pressure effects are not permanent in the normal eye, but 
there is no consensus as to the long-term effects in the glaucomatous eye (Galin 
et a l  1978).
Elevation of IOP following uncomplicated cataract extraction is a common 
though certainly not innocuous phenomenon. Pain, corneal oedema, optic nerve 
damage - glaucomatous or ischaemic - and possible inhibition of wound healing 
are all serious consequnces of increased postoperative IOP (Kolker, 1977; 
Hayreh, 1980; Bartovetal, 1984).
The normal eye ordinarily tolerates transient elevations in IOP without a 
deleterious effect on the ultimate visual outcome. However, in the eye with 
advanced glaucomatous cupping and severe visual field loss, even a transiently 
elevated IOP can have devastating effects on the remaining visual field. In a 
large series of patients with severe glaucomatous damage who underwent 
intraocular surgeiy, Kolker (1977) found that 2 of 23 eyes (8.7%) lost central 
vision after cataract extraction. The loss was attributed to elevation of IOP
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postoperatively.
The early cataract IOP rise in glaucoma patients is greater both in 
frequency and magnitude than that reported in similar cataract surgery in non- 
glaucomatous eyes. (Savage et a l  1985; McGuigan et a l  1986; Krupin et al. 
1989; Calissendorff and Hamberg-Nystrom, 1993).
Therefore, the strong possibility that Healon exacerbates IOP increases 
due to surgery potentially places glaucomatous eyes at even greater risk. An 
anterior chamber filled with Healon may stress the ability of the outflow 
mechanism to eliminate it in a timely fashion, especially if there is a history of a 
compromised outflow. This condition could be extremely dangerous if  the 
pressure rises high enough to cause closure of the central retinal artery (Hoffer, 
1982). The glaucomatous eye already has a compromised outflow system that 
would be expected to tolerate stress poorly. A number of other obstructing 
substances are present in the perioperative period to lead to such a decrease in 
outflow facility. In glaucomatous eyes because their pupils are often 
insufficiently dilated due to long-term miotic therapy or previous laser and 
surgical therapy, sphincterotomy is often required. Despite sphincterotomy, the 
width of the opening during capsulotomy and irrigation-aspiration is often 
considerably smaller than in normal eyes with cataract. Hence, there is more iris 
trauma and more inflammatory mediators are released.
High ocular pressure can decrease blood flow in the optic nerve head 
(Hayreh, 1980) since blood flow is dependent on perfusion pressure which is 
equal to mean blood pressure in the nutrient vessels minus IOP. It is therefore 
possible that individuals with atherosclerotic vessels and poor optic nerve 
blood flow may be very susceptible to even moderate elevation in IOP. Indirect 
evidence for this can be found in the series of cases reported by Hayreh, who
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described 11 patients who developed anterior ischaemic optic neuropathy 
following cataract surgeiy. There is no firm evidence that severe IOP for several 
hours after cataract extraction in healthy eyes is harmful. Perioperative anti­
glaucoma drugs are therefore not routinely used in all patients undergoing 
cataract surgery. However, in view of Hayreh's report, certain patients may 
benefit from the use of perioperative drugs to prevent pressure elevation. Any 
patient who has had anterior ischaemic optic neuropathy soon after cataract 
extraction in one eye is probably at great risk to develop it in his second eye 
after cataract surgeiy. Hayreh recommends that such a patient should receive 
perioperative acetazolamide and timolol. The use of these drugs should also be 
considered in any patient who has had atherosclerotic anterior ischaemic optic 
neuropathy, not related to cataract surgeiy or who has well documented diffuse 
atherosclerosis (i.e. coronary heart disease, cerebral infarction and/or severe 
claudication). Furthermore, such patients should also have their IOP measured 
4-8h after surgeiy so that additional pressure-lowering treatment can be given if 
prophylactic medications fail to prevent severe ocular hypertension.
The possibility that the use of Healon can, in itself, cause increased pres­
sure means that it must be used with care. If any method of obviating that risk 
can be found, it would be an invaluable contribution to safe ophthalmic surgery, 
since it undoubtedly offers many benefits.
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1.4 ASCORBIC ACID
1.4.1 Introduction
Ascorbic acid (AA), also referred to as L-ascorbic acid or vitamin C, is a water- 
soluble vitamin widely distributed in the animal and plant kingdoms. It is of 
major importance in nutrition, maintenance of good health and the food 
industry. Scurvy is the deficiency disease caused by lack of AA and has been 
known since the time of crusades especially among Northern European 
population, who subsisted on diets lacking fresh fruits and vegetables. In 1932, 
the anti-scorbutic factor from lemon juice was isolated (Waugh and King, 
1932).
1.4.2 Chemistry of ascorbic acid
AA is a six-carbon ketolactone (Figure 11) with molecular weight of 176.1 
(CgH^Os) structurally related to glucose from which is synthesized both 
chemically and biologically.
AA is a potent reducing compound which is reversibly oxidized in the 
body to dehydro-L-ascorbic acid (DHAA), which is also biologically active 
(Figure 11). DHAA can be converted by further oxidation to diketogulonic acid 
which is biologically inactive. AA has an optically active carbon atom and 
antiscorbutic activity resides almost totally in the L-isomer. Another isomer, 
erythorbic acid (D-isoascorbic acid or D-araboascorbic acid or D-erythorbic 
acid or D-ascorbic acid) has very weak antiscorbutic action but has a similar 
redox potential. The reason for the lack of stronger antiscorbutic action of
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erythorbic acid is probably the incapacity of the tissues to retain it in the 
quantities in which AA is stored.
h, .  H O H sC
L-Ascorbic acid Dehydro-L-ascorbic acid
(reduced) (oxidized)
Figure 10. Structural formulae of L-ascorbic acid and dehydro-L-ascorbic 
acid.
Although it is called an acid, AA is actually not a carboxylic acid but a 
lactone and an enediol, and it is the enediol group (-C(OH) = C(OH)-) which is 
mainly responsible for the molecule’s acidic and reducing properties. The 
reversible oxidation-reduction with DHAA is AA's most important chemical 
property and the basis of its known physiological activities. AA is a 
monovalent anion at physiological pH. Solid ascorbic acid is stable when dry 
and gradually darkens on exposure to light. Degradation reactions of AA in 
aqueous solution depend on several factors such as pH, temperature, the 
presence of absence of oxygen and the presence or absence o f metals. In 
aqueous solution it is more sensitive to alkali than to acids. It is most stable at 
pH 4-6. Ascorbic acid is sensitive to heat. In the presence of oxygen and heat, 
it is oxidized at a rate proportional to the temperature rise. DHAA undergoes
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irreversible hydrolysis to diketogulonic acid. Most metals, especially copper, 
catalyse the oxidation of AA. Metaphosphoric acid inhibits the catalytic 
oxidation of ascorbic acid by copper by chelating the copper in a non-ionic 
form that prohibits the initial formation of a complex with AA. Another 
catalytic reaction which accounts for loss of the vitamin occurs with enzymes 
such as AA-oxidase (ascorbate oxidase). Metaphosphoric acid inactivates AA- 
oxidase (Sauberlichetal, 1982).
1.4.3 Biosynthesis of ascorbic acid
The human organism cannot make its own AA because through evolution 
and genetic mutation it has lost a particular enzyme system (L-gulono-gamma- 
lactone oxidase) which can transform a sugar like glucose or galactose into AA. 
Thus, man (as well as guinea pig and monkey) must rely upon outside sources 
of AA to cover their needs. However, rabbits,like most other animals, possess 
the enzyme system and can produce AA. The liver is the site of AA synthesis 
(Chatterjee, 1973).
1.4.4 Physiological functions of ascorbic acid
AA functions as a cofactor in a number of hydroxylation and oxidation 
reactions by transferring electrons to enzymes that provide reducing equivalents 
(Levine, 1986). Thus, it is required for or facilitates the conversion of certain 
proline and lysine residues in procollagen to hydroxyproline and hydroxylysine 
in the course of collagen synthesis, the oxidation of lysine side-chains in 
proteins to provide hydroxylysine for carnitine synthesis, the conversion of folic
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acid to folinic acid, microsomal drug metabolism and the hydroxylation of 
dopamine to form noradrenaline (Marcus and Coulston, 1991). AA promotes 
the activity of an amidating enzyme thought to be involved in the processing of 
certain peptide hormones, such as oxytocin, antidiuretic hormone and 
cholecystokinin. By reducing non-haem ferric iron to the ferrous state in the 
stomach AA also promotes intestinal absorption of iron. In addition, AA plays 
a role, albeit a poorly defined one, in adrenal steroidogenesis. At the tissue 
level, a major function of AA is related to the synthesis of collagen, 
proteoglycans and other organic constituents of the extracellular matrix in such 
diverse tissues as tooth, bone and capillary endothelium.
AA is an antioxidant and free radical scavenging nutrient protecting cells 
from damage by oxidants (Padh, 1991). Free radicals can be damaging to 
biological systems. Some evidence exists that AA has a number of 
physiological effects, the mechanisms of which are not understood. A few of 
these effects are: detoxification of histamine, phagocytic functions of 
leukocytes, infections, metabolism of drugs (induction of microsomal enzymes), 
formation of nitrosamine, expression of acetylcholine receptor, leukotriene 
biosynthesis and lipid metabolism.
A number of enzyme systems are stimulated by AA. AA keeps the metal 
ions in these enzymes in their reduced forms and it may have no obligatory role 
in catalysis (Padh, 1991).
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1.4.5 Absorption and excretion of ascorbic acid - Assessment of 
nutritional status
AA is readily absorbed in the gastrointestinal tract by an energy Na+- 
dependent active transport mechanism and absorption of dietary AA is nearly 
complete (Kallner et al, 1977). When exogenous AA is given in a single oral 
dose, absorption decreases from 75% at lg to 20% at 5g. Both gastrointestinal 
absorption and renal tubular reabsorption of AA appear to be saturable 
processes (Melethil et al, 1986). AA is present in the plasma and is 
ubiquitously distributed in the cells of the body.
Although no data have been found to clearly show that any one tissue or 
organ acts as a storage reservoir of AA, leukocytes must be regarded as likely 
candidates.
Loh and Wilson (1971) who worked with subjects, who had been 
receiving a daily supplement of the vitamin for several weeks, showed that there 
was good correlation between leukocyte and plasma concentrations only until 
the leukocytes were saturated with the vitamin. Thereafter, there was no further 
change in the leukocyte AA concentration, although the plasma level continued 
to rise reflecting increased intake. These correlations suggest that leukocyte 
levels reflect the amount of AA available for storage, while plasma AA levels 
reflect the metabolic turnover rate. The above report is in good agreement with 
a more recent study (Omaye et al. 1986).
During vitamin C repletion leukocyte AA responded to dietary intake of 
the vitamin but not as rapidly as plasma AA (Omaye et al. 1986).
In addition, leukocyte AA levels dropped slowly during depletion, only 
reaching zero just before the onset of clinical symptoms of scurvy. For these
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reasons, leukocyte AA levels are considered as a better indicator of vitamin C 
status than plasma. Adequate ingestion of vitamin C is associated with AA 
concentrations in plasma over 5pg.ml“l (28 pM) whereas concentrations of 
1.5pg.ml"l (8.5pM) are seen in individuals with frank scurvy (Marcus and 
Coulston, 1991). When the latter value (8.5pm) is reached the total body store 
of the vitamin at this time approximates 300mg. When the intake of ascorbate 
is raised, the concentration in plasma also increases at first linearly. Relatively 
few studies have examined the disposition kinetics of AA in humans after 
administration of exogenous high doses. The elimination half-life of the 
ascorbate pool in humans is approximately 16 days (Tietz, 1986). In contrast to 
this relatively slow turnover time, the exogenous high dosage of ascorbic acid, 
in excess of the body store, appears to be eliminated rapidly. In a human study, 
healthy volunteers’ body stores have been saturated with the vitamin by 
receiving lg of AA daily for several weeks. After this dosing period, saturation 
was assumed when urinary recoveries of AA (during 24h) on two occasions, 
separated by 3-7 days were within ± 10% of each other. The elimination half- 
life following an iv injection of lg of ascorbate was found to be 3h (Yung et a l  
1978). Following a single oral administration of a range of AA megadoses (0.5- 
20g), Melethil et al (1987) similarly reported that plasma AA levels peaked at 
3h post-dosing and returned to pretreatment values at 10-12h. However, Zetler 
et al (1976) estimated the elimination half-life as 13-29h, values considerably 
greater than the previous study.
The majority of dietary AA is eliminated by the kidney. One route of 
metabolism of AA in man involves its conversion to oxalate. In addition to the 
presence of AA, DHAA and oxalate in urine, lesser amounts of a number of 
catabolites are also present.
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1.4.6 Human requirements for ascorbic acid
The recommended dietary allowances (RDA) for AA is 30mg/day in 
Britain and 60mg/day in USA. Under special circumstances more AA may be 
required to achieve normal concentrations in the plasma. For example, South 
African miners have been observed to require 200 to 300mg of vitamin C daily 
to maintain a plasma concentration of 7.5pg.mH (Visagie et al. 1975). 
Requirements may increase in certain diseases, particularly infectious disease 
and also following surgery (Irvin et al. 1978). In its latest recommendations 
(1989) the National Research Council of the United States has suggested higher 
intake (100 mg/day) for smokers and an increment of 10 mg/day for pregnant 
women. Determination of the optimum requirement for AA has unfortunately 
remained a controversial topic; amounts of up to several grams per day have 
been advocated in the public press as well as in professional journals (e.g. 
Pauling, 1970).
1.4.7 Food sources of ascorbic acid and scurvy
AA is widely distributed in both plants and animals probably in 
equilibrium with DHAA. It occurs in significant quantities in fruits (especially 
citrus fruits) and fresh vegetables.
Today, incidents of scurvy surface occasionally in infants fed exclusively 
on cow's milk which is deficient in vitamin C, in aged persons on limited diets, 
and in adults where there is associated poverty, alcoholism, and nutritional 
ignorance. Evidence exists showing that even with undefined scorbutic
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symptoms, vitamin C levels can be low, causing marked diminution in 
resistance to infections and slower healing of wounds.
1.4.8 Ingestion of megadoses of ascorbic acid
Reports suggesting that daily intake of megadoses (gram doses) of AA are 
beneficial for the prevention and treatment of several disorders, including 
cancer, have led to widespread consumption of vitamin C supplements. Despite 
contradictory reports, the consensus from an extensive literature review by 
Rivers (1987) is that these adverse health conditions are not improved by 
ingesting large doses of ascorbic acid.
Several reviews of the safety of megadoses of vitamin C concur that AA is 
safe at very high levels of intake for prolonged periods of time (Rivers, 1987; 
Gerster and Moser, 1988; Hathcock, 1991). In addition, adverse affects have 
not been reported in recently published placebo-controlled, double-masked 
studies with dosages of vitamin C up to lOg/day taken for several years 
(Moertel et al. 1985; Bordia and Verma, 1985; Bucca et al. 1990; Taylor et al. 
1991).
1.4.9 Factors that affect ascorbic acid nutritional status
Low dietary intake of AA leads to low plasma and leukocyte j 
concentration of ascorbate, low urinary excretion of the vitamin and eventually 
to the appearance of clear deficiency signs and symptoms. However, a number 
of other factors can also affect the apparent vitamin C nutritional status 
regardless of the intake of the vitamin.
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a) Age: A number of surveys have shown that old people have low plasma and 
leukocyte AA levels. This can be attributed to a great extent, to a low intake of 
vitamin C where there is associated poverty, alcoholism and nutritional 
ignorance. However, there is also some evidence that ageing may affect 
vitamin C reserves in the body, regardless of intake. A number of studies in 
man and guinea pigs have shown that, allowing for variations in intake, there is 
an age-related fall in plasma and leukocyte AA concentration (Brook and 
Grimshaw, 1968; Burr and Rajan, 1972; Davies et al. 1976; Bates et ah 1979; 
Newton et al. 1985).
b) Sex: Most of the surveys that have shown age-related changes in vitamin C 
status have also shown a marked sex difference. Women tend to have a higher 
concentration of AA in plasma and leukocytes than do men; recent studies have 
shown that plasma AA levels are higher for females than for males having the 
same intake of AA (Jacob et al, 1988; Taylor et ah 1991)
c) Oral contraceptive agents: Rivers (1975) reviewed a number of studies of 
interaction between oral contraceptives and vitamin C status and concluded that 
a fall in plasma and leukocytes AA concentrations occur in women taking oral 
contraceptive agents.
d) Smoking: Cigarette smoking may adversely affect ascorbic acid metabolism 
in humans and a number of studies have suggested that plasma and leukocyte 
AA levels are reduced in smokers as compared with non- smokers (Pelletier, 
1970; Hoefel, 1977; Schectman et al, 1991)
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1.4.10 Determination of ascorbic acid
Various procedures based on the reduction-oxidation properties of AA are 
used for determination of AA and DHAA in foods and biological samples. 
Titrimetric, fluorometric or spectrophotometric principles are used for the 
analysis (Roe and Keuther, 1943; Denson and Bowers, 1961). Depending upon 
the method selected, either the reduced form or the oxidized form of AA 
(DHAA) or total AA levels can me measured. Although often quite accurate, 
the techniques can be laborious and time consuming (Johnsen et a l  1985). In 
addition, interfering substances present in the samples may affect the specificity 
and accuracy of the measurement. Recently, due to advances in high- 
performance liquid chromatography (HPLC), quantitative measurement of 
ascorbic acid and its metabolites have become possible. Advantages of HPLC 
techniques include: minimum sample preparation, fast analysis time, high 
specificity and sensitivity (Pachla and Kissinger, 1976; Tsao and Salimi, 1981). 
In addition, they offer the feasibility of quantitation in extremely small volumes 
and in specimens with very low concentrations; this is a major advantage in 
biochemical and particularly in ocular research due to the small volume of 
sample which can usually be obtained.
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1.5 ASCORBIC ACID AND THE EYE
1.5.1 Introduction
Harris (1933) and Birch and Dann (1933) first discovered a much higher 
concentration of AA in aqueous humour than in plasma; this has since been 
confirmed by several investigators (Table 4). High levels of AA have also been 
found in other ocular tissues, notably lens and vitreous (Table 4), but there are 
wide differences in the distribution of AA within the eye in different species. 
DHAA is also present in the ocular tissues but at lower extent (Taylor et a l 
1991).
1.5.2 Role of ascorbate in the eye
The exact role of AA in the eye is still not clear and it has been suggested 
that its most important role may not yet be known (Heath, 1962; Garland, 1991; 
Rose and Bode, 1991). Protection against oxidative damage, by scavenging 
reactive free radicals generated by sunlight, appears to be one of the most 
notable functions of this compound.
Some of the other putative functions of ascorbic acid in the eye include:
1. Promotion of comeal wound healing, especially of deep ulcers following 
alkali bums (Levinson et al. 1976; Pfister and Paterson, 1980; Nirankari et 
al, 1981).
2. Modulation of metabolism of arachidonic acid in the iris, ciliary body and 
cornea (Hurst et ak 1989).
3. Modulation of production of fibronectin and laminin and synthesis of
60
glycosaminoglycans in trabecular meshwork cell culture (Higginbotham et 
al, 1988; Schachtschabel et_al, 1989; Yue et a l  1990).
4. Operation as a redox system (ascorbic acid/dehydroascorbic acid) linked 
to the maintenance of reduced pyridine nucleotide levels (Reddy, 1971; 
Varma et ak 1987).
5. Development of the lens and maintenance of its transparency during 
development (Garland, 1991).
6. Elimination of oxygen (thus decreasing the probability of oxidative insult) 
from the lens (Pirie, 1965a 1965b; Spector and Gamer, 1981; Lohman et 
al, 1986; Gamer et ak 1983; Linklate et al. 1990; Eaton, 1990) and 
cataract prevention (Jacques et al. 1988; Robertson et ak 1991).
7. Protection against UV irradiation (Ringvold, 1980; Chandra et al. 1986; 
Devamanoharan et a l 1991). Higher aqueous ascorbic acid levels are 
found in diurnal than in nocturnal animals; it may be an adaptation that 
protects the eye against solar irradiation. (Reiss et ak 1986).
8. Prevention of riboflavin-mediated light-induced damage to the cation 
pump and decrease of the photoperoxidation of the membranes in the lens. 
In both cases damage is thought to be the result of superoxide generation 
(Varma et a l  1979; Varma and Richards, 1988).
9. Protection against light-induced loss of retinal pigment epithelial cells and 
photoreceptor cells (Khatami et ak 1986; Organisciak et al, 1990).
10. Inhibition of the activity of polymorphonuclear leukocytes in inflammed 
ocular tissues acting as endogenous anti-inflammatory factor (Williams et 
al, 1984; Williams and Patterson, 1986).
11. Contribution in delaying age-related macular degeneration (Tso, 1985; 
Eye Diseae Case-Control Study Group, 1993).
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1.5.3 Ascorbate, free radicals and the eye
The term free radicals represents reactive molecules with an unpaired 
electron. Free radicals are of varying degrees of toxicity to the body. Many of 
them are derived from atmospheric oxygen. When a single electron is added to 
the most stable state or ground state O2 molecule, the product is the superoxide 
anion radical:
° 2  - >  0-"2
The body is endowed with a family of enzymes referred to as superoxide 
dismutases which metabolise 0-"2 to H2O2:
20 "2 + 2Hh—> H2O2 + O2 
Direct two-electron reduction of O2 also leads to H2O2. Hydroxyl free 
radicals may also be generated by the reaction of superoxide radical with 
peroxide (Haber-Weiss reaction):
0  "2 + H2O2 ~'> O2 + OH" + OH- 
as well as via H2O2 in the presence of Fe2+ or Cu+(Fenton reaction):
Fe2+ + H202 Fe3+ + OH" + OH- 
Cu+ H202 -* Cu2+ + OH" + OH- 
Hydroxyl radicals are highly reactive and can directly damage cell components. 
AA and glutathione are part of the biological system that protects against the 
damaging oxidative effects of free radicals and peroxides that are continuously 
produced as minor by-products of tissue metabolism. Since such reactions are 
enhanced by the presence of oxygen and by light, the ocular tissues and fluids 
are at considerable risk.
In the aqueous, the problem is exacerbated by the absence of the major
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detoxifying enzymes (superoxide dismutase, catalase, glutathione peroxidase) 
and by the presence of riboflavin which catalyses the formation of hydrogen 
peroxide.
AA present in the aqueous humour at high concentrations can react with 
oxygen or hydroxyl radicals to yield hydrogen peroxide, becoming oxidized to 
DHAA. The hydrogen peroxide which is itself toxic to the cornea at high 
concentrations (Riley and Giblin, 1983), can then be reduced to water by non- 
enzymatic reaction with glutathione, with formation of the disulfide. Thus, the 
continuous supply of ascorbate and glutathione may effectively detoxify any 
injurious free radicals produced in the anterior segment.
Ionising radiation often induces cataract, perhaps, by increased formation 
of hydroxyl and superoxide radicals. AA is present at high concentrations in 
the aqueous humour, lens and cornea of man and many animals. Its ability to 
scavenge 0-"2, OH- and singlet oxygen (reactive form of oxygen) may be of 
importance, although on the other hand, it has been suggested that light- 
induced degradation of AA in the aqueous humour may be a source of hydrogen 
peroxide that has to be removed by glutathione, peroxidase and catalase. 
Ascorbate has been observed to protect the lens ion-transporting ATPase 
enzyme against damage by an O "2 generating system in vitro (Halliwell and 
Gutteridge, 1985).
1.5.4 Ascorbate in the aqueous humour
AA is present at high levels in the aqueous humour of many species. In 
the human aqueous humour the concentration of AA is some 10-30 times that in 
the plasma (Table 4). Koskela et al (1989) suggested that the high
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concentration of AA in the aqueous is a long- term adaptation to solar radiation. 
This gives support to the original hypothesis o f Reiss et al (1986) that AA is 
present when needed to protect against sunlight. McGahan (1985) evaluated the 
levels of reduced and oxidized AA in plasma and in aqueous and vitreous of the 
rabbit. Although no DHAA was detected in the ocular fluids, it was present in 
plasma, sometimes at a concentration exceeding that of the reduced molecule.
1.5.5 Aqueous humour ascorbate saturation
Active transport sytems usually have a limit beyond which an increase in 
substrate concentration will produce no further increase in transport. When this 
limit is reached, the system is said to be 'saturated'. The ascorbate transport 
system into the aqueous humour is saturable.
At high serum concentrations of AA, there is a maximum rate o f transfer 
of this substance into the aqueous humour in different species including man 
and rabbit. As the blood level of AA rises, the aqueous AA level reaches 
saturation. Kinsey (1947) has demonstrated that in the rabbit, the AA 
concentration in the aqueous humour increased rapidly within lh  with 
increasing serum concentrations until the level into the aqueous reached 
500pg.mH (ie, twice the normal values). This occurred when the 
concentration in the serum was 30pg.m H. With higher blood levels, no further 
increase in the quantity of AA in the aqueous humour was observed, even 
though the concentration in the serum was elevated to 1300pg.ml'l. The 
saturation level of AA (500pg.ml"l) in the aqueous humour was maintained as 
long as the blood level remained constant. Linner (1952) has shown that the 
maximum rate of transfer of AA across the BAB in guinea pigs is reached at a
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TABLE 4: CONCENTRATIONS OF ASCORBIC ACID IN PLASMA,
AQUEOUS HUMOUR, VITREOUS BODY AND LENS
Plasma Aqueous Vitreous Lens Species Reference
(p,g.ml- l)  humour body (pg/g
(p,g.ml"l) (pg.ml-!) wet
tissue)
3.5 167 Rabbit Kinsey, 1953
7 195 81 Rabbit Reddy and Kinsey, 1960
128 Rabbit Heath et al, 1961
8 153 Guinea pig Heath et al, 1961
7 186 81 Human DeBerardinis et al, 1965
3.5 208 Monkey Gaastarland et al,1979
5.6 176 77 Rabbit McGahan, 1985
0.8 200 206 Human Ringvold et al, 1985
186 Human Reiss et al, 1986
10 160 360 190 Human Varma, 1987
4.1 346 70 130 Rabbit Varma, 1987
132 Guinea pig Varma, 1987
5.3 135 209 Human Taylor et al, 1991
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plasma AA level of about 20pg.ml"l and that the saturation concentration of 
AA in the aqueous humour is about 300pg.ml"l. The same investigator 
subsequently found (Linner, 1954) that in man, the maximum rate of transfer of 
AA across the BAB is reached at a plasma concentration of about 10pg.ml“l, 
while the concentration of AA in the aqueous humour rises to about 
220pg.ml“l. By raising the plasma AA level of guinea pigs, saturation kinetics 
can be demonstrated in the aqueous humour (Becker, 1967; Berger et a l  1988). 
The concentration of AA in the aqueous is proportional to plasma AA levels 
over a fairly wide range of values and falls precipitously in scorbutic guinea 
pigs (Linner, 1952; Hughes et ak 1971; Giblin et al. 1984). The dependence of 
aqueous AA on dietary intake was confirmed by Bates and Cowen (1988). It is 
well documented that a decline in vitamin C status occurs in the elderly (Bates 
et ak 1979; Newton et al, 1985) and it was clearly shown that the aqueous 
humour of guinea pigs exhibited an age- related decline in AA levels (Bates and 
Cowen, 1988). In the rabbit, a single either subcutaneous or iv injection of AA 
was able to raise the aqueous ascorbate level up to two to three times the 
original level for at least 8-12h and with a higher dosage of AA this saturation 
level was reached faster than with lower ones (Reim et ak 1978). Other rabbit 
studies also showed that intraperitoneal injection of AA increased the level 
four-fold in the plasma and two-fold in the aqueous humour (Giblin et ak 
1984).
In humans, Ringvold et al (1985) have found that there was a significant 
elevation of aqueous AA in cataractous patients after lOOOmg oral intake 
(500mg x 2, 2 and 12h preoperatively), but not after 500mg administration as a 
single dose 2h before surgery. Taylor et al (1991) described the ability to 
increase AA concentration in plasma and aqueous humour following ingestion
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of a 2g supplement (500mg qid) of ascorbate (165% and 57% increase vs 
unloaded patients in plasma and aqueous humour, respectively).
1.5.6 Ascorbate in the vitreous body
In some species, AA is found in higher concentration in the vitreous body 
than in the plasma; the gradient in rabbits being posterior chamber greater than 
vitreous greater than plasma (Reddy et a l  1961). In cattle, on the contrary, the 
level in the vitreous is half of that in plasma (Balazs, 1960). It is unclear 
whether the ascorbic acid within the vitreous results from diffusion from the 
aqueous humour or from synthesis within the vitreous body (Jacobson, 1967). 
The gel characteristic of the vitreous body does not seem to correlate with the 
AA content; the latter correlated most directly with the dietary intake of AA. It 
has been suggested that AA fulfils a function of HA degradation, breaking the 
linkages responsible for the organisation of the HA molecules (Swann, 1969). 
Nevertheless, the large variation found among animals did not correlate well 
with the viscosity of the gel, nor did it correlate well with the degree of 
syneresis, although the concentration was lower in rabbit embryos than in the 
mother animal (Balazs, 1954, 1968). While its role in liquefaction of the 
vitreous gel is unclear, AA has been found to participate in the absorption of 
ultraviolet rays in the vitreous body (as it does in the aqueous humour).
1.5.7 Ascorbate and the lens
Varma and Richards (1988) measured AA levels in lens and aqueous in 
eight animal species. The values of lens/aqueous concentrations of ascorbate
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ranged from 0.44 in the rabbit to 2.6 in the horse. Values around 1.0 - 2.0 are 
often presented for man. It has not been determined which form of AA is 
preferred for transport in the lens. It is well documented that there is a rapid 
loss of AA from the tissues of guinea pigs deprived of dietary AA. Hughes et al 
(1971) noted that the brain and the lens are unique in retaining considerable AA 
after other organs have been depleted. Animals were maintained on a scorbutic 
diet for up to 90 days and then killed for procurement of tissues. The 
concentration of AA fell much less rapidly in the lens than in the aqueous and 
vitreous humours. This suggests either that the lens has a remarkable capacity 
to extract AA from surrounding fluids or that AA taken into the lens is more 
tightly sequestered than in most other tissues.
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1.6 DEPOLYMERIZATION OF HYALIURONIC ACID BY ASCORBIC
ACID
Numerous studies have demonstrated tlhat AA depolymerizes HA in vitro 
(Niedermeier et a l  1967; Wong et a l  1981; Miyauchi and Iwata, 1984; 
Motohashi and Mori, 1985). In these studies the rate of AA-induced 
depolymerization is measured either as the loss of viscosity or as the lowering 
of molecular weight of the HA. This depollymerization appears to occur in a 
concentration-related manner (Wong et al, 1981; Motohashi and Mori, 1985; 
Fink and Lengfelder, 1987) at least for AA levels up to lOOO i^M (176pg.ml"l), 
which is approximately the physiological aiqueous humour AA concentration 
(Table 4). The mechanism of AA-induced depolymerization of HA is unclear. 
There is strong evidence that oxygen-derivedl free radicals, especially the highly 
reactive hydroxyl radical, may play an important role in the depolymerization 
process (Wong et al. 1981; McNeil et a l  11985). The presence of traces of 
heavy metals such as iron or copper, which act as catalysts, seems to be critical 
in the reaction of formation of hydroxyl radicals and the following mechanism 
has been suggested (Harris et a l 1972; Womg et a l  1981; Scarpa et ah 1983; 
Motohashi and Mori, 1985). Ascorbic acid acts to maintain the iron ions in the 
ferrous form by reducing ferric ions:
Fe3+ + ascorbate -► Fe2+ + dehydroascorbatte 
then, Fe2+ + O2 Fe3+ 0-"2
and then H2O2 reacts with Fe2+ to produce hiydroxyl radicals:
H202 + Fe2+ Fe3+ + OH“ + OH-
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Hydroxyl radicals are probably the ultimate species that depolymerize 
HA. This reaction scheme can explain the inhibition of depolymerization by 
scavengers of hydroxyl radicals (such as formate, mannitol, thiourea, ethanol) 
and by catalase (Wong et a l  1981). The reports that iron (II) salts enhance the 
AA-induced depolymerization of HA and that the rate o f depolymerization is 
reduced by the specific iron) chelator desferrioxamine, strongly supports the 
theory that the above iron-catalyzed Haber-Weiss reaction regenerating OH- is 
the most probable depolymerizing mechanism for hyaluronate (Harris et al, 
1972; Wong et a l  1981; Motohashi and More, 1985).
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CHAPTER 2
RATIONALE AND SPECIFIC AIMS OF THE STUDY
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RATIONALE AND SPECIFIC AIMS OF THE STUDY
Clinical studies investigating the effect of Healon on postoperative IOP in 
patients who have undergone cataract extraction with or without IOL 
implantation have suggested that within the first 24h potentially dangerous in­
creases in IOP can occur, even if  an attempt is made to remove the Healon. 
Further, an in vitro study has shown that such IOP rises may be due to 
obstruction of the aqueous humour outflow pathways. This suggests that 
Healon-induced IOP rises might be ameliorated if  it was depolymerized into 
smaller molecules which could be more easily cleared by the outflow 
pathways.
Ascorbate, at levels known to be present physiologically in the aqueous 
humour, is known to depolymerize hyaluronate in vitro. In the immediate 
postoperative period, ascorbate levels probably are greatly decreased due to the 
damaging effect of surgical trauma on the blood-aqueous barrier. Some reports 
have also shown that the use of Healon intraoperatively may exacerbate the 
postsurgical breakdown of the barrier and/or interfere with barrier recovery.
Collectively, these studies suggest the general hypothesis that 
postoperative IOP spikes due to the use of Healon in cataract surgery might be 
attenuated by increasing the concentration of ascorbate in the aqueous humour 
in the immediate postoperative period. The following lines of investigation 
were followed in order to address this general hypothesis:
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A. Documentation and study of Healon-induced rise in IOP. More 
specifically:
Specific aim A .l: Study of the magnitude and timecourse of IOP rise in the 
early postoperative period with and without the use of Healon in patients who 
undergo planned ECCE with p/c IOL implantation.
Specific aim A.2: Documentation of the magnitude and timecourse of
obstructive properties of Healon in the human eye in vitro (perfused human 
ocular anterior segment).
B. Test and study of the hypothesis that postoperative IOP rises due to Healon 
might be attenuated by increasing aqueous humour ascorbate to a level which 
might depolymerize hyaluronic acid. More specifically:
Specific aim B .l: Determination of the extent and duration of any change in 
postoperative aqueous humour ascorbate concentration following the trauma of 
surgery in rabbits (in absence or presence of Healon).
Specific aim B.2: Study of the maximum attainable level of ascorbate in the 
aqueous humour by raising plasma ascorbate levels by administration of 
systemic ascorbate.
Specific aim B.3: Study of the effect of ascorbate on any Healon-induced 
change in outflow facility in the human eye in vitro (perfused human ocular 
anterior segment).
Specific aim B.4: Investigation of whether a high concentration of ascorbate 
in the aqueous prevents or attenuates postoperative IOP rises following cataract 
surgery with intraoperative use of Healon.
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CHAPTER 3 
MATERIALS AND METHODS
f
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3.1 CLINICAL STUDIES
Patients admitted to the Department of Ophthalmology, Western 
Infirmary, Glasgow for planned ECCE with p/c IOL between October 1990 
and February 1993 were invited to participate in these studies. Procedures 
were reviewed and approved by the Hospital Ethical Committee and informed 
consent was obtained from all patients meeting the enrolment criteria.
3.1.1 The effect of systemic ascorbate pretreatment on aqueous
humour ascorbate concentration
An initial investigation was conducted to determine the maximum 
increase in aqueous humour ascorbate attainable after systemic pretreatment 
with oral ascorbate in patients undergoing planned ECCE.
Patients: A total of 105 patients agreed to participate in this study. The
patients included 44 males and 61 females ranging in age from 50 to 93 (72.6 ± 
10.1; mean ± SD).
Pretreatment with oral ascorbate: Patients were divided into 5 groups based on 
the amount of ascorbate given|preoperatively: those receiving no ascorbate 
(n=56) or a total dose of lg (n= ll), 2g (n=17), 3g (n=18), or 5g (n=3). 
Demographic data are pesented in Table 5. Oral ascorbate was administered as 
Ascorbic Acid tablets BP 500mg BP (APS Ltd, West Yorkshire, UK) in two 
equal doses administered the evening before surgery (10 pm) and the morning 
of surgery (8 am, one to six hours before surgery). Aqueous humour and 
plasma samples were obtained between 9.00 am and 2.00 pm on the day of 
surgery.
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TABLE 5: PATIENT DEMOGRAPHICS OF ASCORBATE
PRETREATM ENT STUDY
Sex
Age M ale Female
Ascorbate(g) No Mean±SD Range No % No %
0 56 71.2±10.9 50-93 25 45 31 55
1 11 74.8± 8.6 63-86 5 45 6 55
2 17 72.9±10.9 56-92 6 35 11 65
3 18 72.6± 9.7 56-92 7 39 11 61
5 3 71.0±12.5 61-85 1 33 2 66
Collection of aqueous humour samples for analysis of aqueous humour 
ascorbate levels: the patients' pupils were dilated one hour before surgery with 
two drops of phenylephrine hydrochloride 10% (Minims, Smith & Nephew pic, 
Romford, Essex, UK) and two drops of cyclopentolate hydrochloride 1% 
(Minims). During the operation, an aqueous humour sample (30-200pl) was 
aspirated with a microsyringe through a 25 gauge (G) needle prior to entry of 
the anterior chamber after a partial thickness corneoscleral incision had been 
made. Each aqueous humour sample was immediately added to a preweighed 
sample tube containing 200pi of metaphosphoric acid (Aldrich, Milwaukee, 
WI, USA)solution (2.5% in H20).
Collection of plasma samples for analysis of plasma ascorbate levels: a blood 
sample was withdrawn by antecubital venipuncture using an evacuated 
heparinised tube approximately at the same time as the aqueous humour 
collection. The blood was centrifuged for 3 min at 5,000g and a 0.5ml aliquot
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of the plasma was mixed with 0.5ml of metaphosphoric acid solution (2.5% in
h 20).
Both aqueous humour and plasma samples were immediately stored at 
-20°C for up to six weeks until analysis.
3.1.2 Pilot study of plasma ascorbate levels following ascorbate ingestion
Five healthy adult volunteers (four males and one female, 28-50 years of 
age), after giving informed written consent, participated in a study designed to 
determine the timecourse of plasma ascorbate levels following ingestion of a 
single bolus dose.
Each subject ingested lg of ascorbic acid and blood samples were 
obtained at 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 and 24h. Plasma was immediateely 
separated and stored until analysis as described previously. One day prior to 
and during the experimental day the subjects avoided foods known to be high 
in ascorbic acid content. On the experimental day, the subjects ingested the 
assigned dosage on an empty stomach after overnight fast. Food was withheld 
for the next four hours. All subjects were non-smokers.
3.1.3 The effect of Healon upon the immediate postoperative IOP 
and the effect of ascorbate upon the immediate IOP rise as a 
sequel to the use of intraoperative Healon
A prospective, randomized, placebo-controlled double- masked trial was 
conducted to study the magnitude and timecourse of early postoperative rises 
in IOP after cataract surgery with and without the use of Healon. A further
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aim was to investigate whether pretreatment with ascorbate would prevent any 
Healon-induced IOP rise.
Patients: patients undergoing routine, planned, uncomplicated ECCE with p/c 
IOL were enrolled in this study. Exclusion criteria for participation in the 
study included the following:
1. history of intraocular surgery or disease (apart from age-related macular 
degeneration) in either eye
2. preoperative IOP > 2 ImmHg in either eye
3. family history of glaucoma, ocular hypertension or exfoliation syndrome
4. diabetes mellitus or patients taking beta-blockers or corticosteroids
5. state of health precluding proper examination and assessment
Patient data were also excluded from data analysis in the case of any intraoperative or 
postoperative complications. Only one eye per patient could be included in the study. 
The patients were randomized using randomization tables to one of the following four 
treatment groups:
1. no ascorbate (placebo)/no Healon
2. no ascorbate (placebo)/intraoperative Healon (0.1- 0.5ml)
3. ascorbate (2g)/no Healon
4. ascorbate (2g)/intraoperative Healon (0.1-0.5ml)
A total dose of 2g of ascorbate or placebo (as the results of the previous study 
showed that a maximal attainable level of ascorbic acid into the aqueous 
humour could be achieved with this dosage) was given preoperatively in two 
doses as noted above and aqueous ascorbate levels were determined.
A total of 94 patients were entered into the study and 76 completed the 
study. Eighteen patients did not complete the study for the following reasons:
7 required sphincterotomy due to insufficiently dilated pupils; 5 had rupture of
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the posterior capsule with loss of vitreous requiring insertion of an anterior 
chamber IOL; 2 had immediate postoperative macroscopic hyphaema; 1 
developed postoperative endophthalmitis; 1 required a secondary surgical 
procedure due to wound leaking; 2 did not receive the morning dose of 
ascorbate (or placebo). The patients included 37 males and 39 females 
ranging in age from 39 to 92 (71.9±11.5; mean ± SD). Demographic data are 
presented in Table 6 for all patients who completed the study.
TABLE 6: PATIENT DEMOGRAPHICS OF ASCORBATE-HEALON 
STUDY
Sex
Age Male Female
No Mean±SD Range No % No %
No ascorbate/
No Healon 10 71.0±9.9 51-86 8 80 2 20
No ascorbate/ 
Healon 28 72.2±11.4 39-92 13 46 15 54
Ascorbate/ 
No Healon 10 76.0±10.9 50-90 4 40 6 60
Ascorbate/
Healon 28 70.2±12.2 46-91 12 43 16 57
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IOP measurements and surgical procedure: A complete anterior segment 
examination and bilateral IOP measurements with a calibrated Goldmann 
applanation tonometer using a Haag-Streit slit-lamp (model 900) were taken 
the evening before surgery between 4 pm and 8 pm. One drop of lignocaine 
hydrochloride 4% and fluorescein sodium 0.25% (Minims) was applied to both 
eyes before measurement. The mean of two IOP values measured 5 min apart 
was calculated. All pupils of the experimental eyes were dilated lh  
preoperatively as described above. Each operation was performed under 
general anaesthesia or retrobulbar anaesthesia. In the latter case an additional 
topical administration of 2-3 drops of oxybuprocaine hydrochloride (4mg.ml"l) 
(Minims) was applied to the eye before surgery. One drop of chloramphenicol 
eye drops BP (Minims) was instilled to the eye before the beginning of 
surgery.
ECCE with p/c IOL was performed in all cases in a similar fashion by 
one of five experienced ophthalmic surgeons as described below.
A partial thickness superior limbal or clear comeal incision was made 
through 120° with a disposable razor blade knife. A sample of aqueous humour 
was then removed with a microsyringe through a 25G needle and treated as 
described previously, after which a perforating stab incision was made at the 
12 o'clock position. Healon (0.1-0.25ml) was then injected through a 27G 
cannula to deepen the anterior chamber. An anterior capsulotomy was 
performed using a cystotome by an envelope-like (endocapsular) technique in a 
horizontal plane 1/4 - 1/3 superiorly. A gentle hydrodissection and 
mobilization of the nucleus of the lens was carried out with a needle and 
complete opening of the remaining incision (120°) was made with scissors. 
The nucleus was expressed with an irrigating Vectis. The cortical remains
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were aspirated with a syringe during gravity-fed irrigation through a coaxial 
cannula. Hartmann's solution (Baxter Healthcare, Norfolk, England)with 
adrenaline BP (1:10^) was used as the irrigant. The posterior capsule was 
manually vacuum- cleaned or polished and additional Healon (0.1-0.25ml) was 
injected in some cases to separate the anterior and posterior capsules and to 
reform the capsular bag before IOL implantation. A C-loop or tripod posterior 
chamber intraocular lens was inserted and every effort was made to place the 
haptics in the capsular bag. The central part of the anterior capsule was then 
removed. Immediately after lens implantation and centration, an 
irrigating/aspirating procedure was undertaken in an attempt to remove as 
much Healon as possible. The incision was closed with continuous or 
interrupted 10-0 monofilament Polyamide (nylon) sutures or interrupted 8-0 
coated Vicryl sutures. The fomix-based conjunctival flap was reapproximated 
with one or two coated Vicryl 8-0 sutures. One drop of chloramphenicol eye­
drops BP (Minims) was applied to the eye at the end of surgery. No miotics, 
antibiotics or steroids were given and the eyes were not bandaged.
Although the Healon syringe has no calibrations the volume used for each 
patient was estimated by measuring the length of the column of residual 
Healon in the syringe.
The eyes that did not receive intraoperative Healon were operated on with 
an identical technique with the exception that Hartmann's solution with 
adrenaline was used instead of Healon. The decision to use Healon was made 
before the start of surgery.
Postoperative IOP was measured approximately 6h (5-7h) and 24h (22- 
25h) after surgery by the same investigator (SDK) with the same applanation 
tonometer with patients in a sitting position as preoperatively.
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Analysis of aqueous humour and plasma ascorbate
High-performance liquid chromatography (HPLC) on ODS silica with 
cetyltrimethylammonium bromide as an ion-pairing reagent and 
electrochemical detection (ECD) was used to determine ascorbic acid in human 
and rabbit aqueous humour and plasma as described in detail by Watson et a l  
1993. Hydroquinone was used as the internal standard.
Chemicals: Ascorbic acid, hydroquinone, cetyltrimethylammonium bromide, 
metaphosphoric acid, sodium acetate and glacial acetic acid were obtained 
from Aldrich Chemical Co. (Gillingham, Dorset, UK). HPLC grade 
acetonitrile and water were obtained from Rathbum Chemical Co. 
(Walkerbum, Peebleshire, UK).
Preparation of samples: Stock solutions of hydroquinone and ascorbic acid 
(each lm g.m l'l in water) were freshly prepared each time before analysis.
200pl of trichloroacetic acid (30% solution) was added to a 50pl sample 
of aqueous humour which had been preserved with metaphosphoric acid. The 
sample was then centrifuged (9000g.min); lpg of hydroquinone was added 
to lOOpl of the supernatant which was then diluted to 1ml with mobile phase. 
A 50pl volume of the sample was then injected into the chromatograph using 
an autosampler.
200pi of trichloroacetic acid (30% solution) was added to the plasma 
samples which had been preserved with metaphosphoric acid. The sample was 
then centrifuged (15000g.min) to remove precipitated protein; lpg of 
hydroquinone was added to 500pi of the supernatant which was then diluted to 
lml with the mobile phase. A 50pl volume of the sample was then injected
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into the chromatograph using an autosampler.
Instrumentation: A Hewlett-Packard 1082 HPLC system with an autosampler 
was used in the analyses. The instrument was fitted with a 5pm spherisorb 
ODS-1 reversed phase column which was protected with a SGE ODS-1 guard 
cartridge system (Burke Analytical, Glasgow, UK). The HPLC system was 
linked to an electrochemical detector (LC-4A amperometric detector; 
Bioanalytical Systems). The potential of the detector was set at 0.6V  versus 
an Ag-AgCl reference electrode. Oxygen-free nitrogen was used for the 
operation of the pneumatically driven autosampler. The mobile phase was 
prepared by dissolving sodium acetate (0.08M) and cetyltrimethylammonium 
bromide (0.001M) in acetonitrile-water (5:95, v/v); the pH of the solution was 
adjusted to pH 4.2 with glacial acetic acid. The flow rate was adjusted to 
lml.min’ l.
Calibration curve: Solutions containing lpg  of hydroquinone and 0.5-5pg of 
ascorbic acid in 1ml of the mobile phase were prepared. The solutions were 
then injected into the chromatograph. A standard curve was constructed using 
a fixed amount of hydroquinone as the internal standard and varying the 
amount of ascorbic acid over the range 0.5-5pg.ml"l. The curve was linear 
(r=0.998). The precision was determined by injecting five replicates of the 
same sample of diluted aqueous humour containing 246.4pg.ml"l of ascorbic 
acid; the RSD was 1.49%. The reproducibility was determined on five 
separate analyses of the same sample of aqueous humour containing 
311.8pg.ml"l of ascorbic acid; the RSD was 1.63%. The retention times of 
ascorbic acid and hydroquinone were approximately 4 and 6min, respectively. 
Standard solutions of ascorbic acid and hydroquinone were prepared each time 
before analysis.
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3.2 ANIMAL STUDIES
A total of 52 adult New Zealand white rabbits (2.5-4.6 kg, either sex) 
were used in these studies. The rabbits were housed in the Physiology Animal 
House, University of Glasgow, subjected to natural daylight horns and given 
free access to water and food. The rabbits were handled in accordance with 
Home Office regulations. Prior to experimental manipulation, the eyes were 
examined with the surgical microscope and determined to be normal and free 
of inflammation.
When pretreatment with ascorbate was required, rabbits were subjected to 
oral administration of Sodium Ascorbate (Sigma Chemical Co, St Louis, MO, 
USA) solution (lOOmg.ml‘ 1 in H2O) using a 10ml syringe fitted with a silicone 
rubber tube (5cm in length). The dose given was 50mg/kg body weight, 3h 
before surgery.
Blood samples were withdrawn by puncture of the marginal ear vein and 
then treated as described in clinical studies.
Heparin (Monoparin, CP Pharmaceutical, Wrexham, UK) was 
administered by iv injection (2000U.Kg"l) in the marginal ear vein to all 
rabbits lh before surgeiy.
Anaesthesia was induced and maintained with nitrous oxide-oxygen 
(75:25%) containing halothane BP (3%) in an open system with evacuation of 
exhaled gases.
Both surgery and subsequent paracentesis were carried out under general 
anaesthesia with supplementary topical anaesthesia using amethocaine 
eyedrops BP (Minims). A partial thickness corneal incision (120°) was made 
with a disposable razor blade knife. A sample of aqueous humour (60-100pl)
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was removed with a microsyringe through a 27G needle and immediately 
mixed with an equal volume of metaphosphoric acid solution (2.5% in H2O), 
after which a perforating stab incision was made at the 12 o'clock position, 
followed by a complete (120°) opening with scissors. Hartmann's solution 
containing heparin (lO U .m H ) was infused into the anterior chamber and the 
incision closed after 15 min with interrupted nylon sutures (10-0).
Paracentesis was performed with a microsyringe through a 27G needle to 
penetrate the cornea l-2mm from the unoperated limbus.
Chloramphenicol eye drops BP (Schering, Suffolk, England) were 
instilled before and after surgery.
In all cases, an aqueous humour sample from the fellow untouched eye at 
48h served as a contralateral control. At the end of each experiment, 
euthanasia was carried out using nitrous oxide and halothane. Both aqueous 
humour and plasma samples were stored at -20°C for up to six weeks until 
analysis of ascorbate by HPLC as described in clinical studies.
3.2.1 Timecourse of the effect of surgery on aqueous humour
ascorbate levels
The effect of surgery (corneal incision) on aqueous humour ascorbate 
levels at different postoperative timepoints was determined unilaterally in two 
series of experiments. In the first series (n=7), corneal incision and withdrawal 
of aqueous humour was performed unilaterally and further samples were 
obtained at 6, 12, 24 and 48h postoperatively. In the second series (n=7), 
further samples were obtained at 2, 5, 8, 24 and 48h.
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3.2.2 Plasma ascorbate levels following oral administration of ascorbate
A total of 7 rabbits was used in this study designed to investigate the 
timecourse of plasma ascorbate levels following a single oral administration of 
ascorbate. Each rabbit received 50mg/Kg body weight of ascorbate and blood 
samples were obtained at 0, 45, 90, 135, 180, 225, 280, 325, 615 and 795 min.
Plasma was immediately separated and later assayed for ascorbic acid by 
HPLC as described in clinical studies.
3.2.3 The effect of surgery and Healon on aqueous humour ascorbate
concentration
A study designed to investigate the effects o f surgical procedures and 
Healon on aqueous humour concentration of ascorbate included 4 groups as 
follows:
1. comeal incision alone/no Healon (n=5)
2. comeal incision alone/Healon (0.25ml) (n=5)
3. comeal incision and lens removal/no Healon (n=6)
4. comeal incision and lens removal/Healon (0.5ml) (n=6)
Withdrawal of aqueous humour was performed at the time of surgery and 
a further sample was obtained at the end of surgery from both the experimental 
and contralateral control eyes.
Comeal incision, lens removal and all surgical manipulations were 
conducted as previously described.
Intraoperative Healon was used to deepen the anterior chamber (0.25ml) 
and to reform the capsular bag (0.25ml). No IOL was inserted and no attempt
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was made to remove the Healon at the end of surgery.
The eyes that did not receive Healon were operated on with an identical 
technique with the exception that Hartmann's solution with heparin was used 
instead of Healon.
Analysis of aqueous humour ascorbate levels was performed by HPLC as 
described in the clinical studies.
3.2.4 The effect of systemic ascorbate pretreatment on postoperative 
aqueous humour levels of ascorbate following the 
intraoperative use of Healon
A total of 9 rabbits divided into two groups was used in this study 
designed to investigate the effect of systemic ascorbate pretreatment on the 
postoperative aqueous humour concentration of ascorbate following the use of 
Healon:
1. Corneal incision and lens removal/Healon (0.5ml) + ascorbate 
pretreatment (n=5)
2. Corneal incision and lens removal/Healon (0.5ml) (n=4)
The rabbits of group 1 received, orally, 50mg/kg body weight of ascorbate 3h 
preoperatively. Corneal incision, lens removal, intraoperative use of Healon 
and all surgical manipulations were performed as previously described. 
Withdrawal of aqueous humour was performed at the time of surgery and 
further samples were obtained at 6 and 48h.
The rabbits of group 2 (control) did not receive ascorbate pretreatment 
and followed an identical procedure.
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3.3 IN VITRO STUDIES
Studies were conducted in perfused ocular anterior segments of human 
eyes to determine the effect of Healon on facility of outflow and the effect of 
ascorbate on the Healon-induced reduction in outflow facility.
Human eves: A total of 28 normal human eyes, from donors having no history 
of intraocular surgery or intraocular disease ranging in age from 60 to 92 were 
used in these studies. Eyes were obtained from the New England Eye Bank 
(Boston, MA, USA) or from the National Disease Research Interchange 
(NDRI; Philadelphia, PA, USA).
Preparation of eves for perfusion: Tissue was dissected and placed into culture 
medium (Optisol, Chiron Inc, Irvine, CA, USA) within 12h of death and 
shipped chilled to Boston via overnight mail. Techniques previously described 
were used for the preparation and perfusion of tissue (Erickson-Lamy et al, 
1991; Erickson-Lamy, 1992).
Anterior segments were dissected (usually by the eye banks) under sterile 
conditions as follows. The eye was bissected at the equator, and the anterior 
segment was dissected. The lens zonule was cut and the lens removed, after 
which the iris was grasped at the pupillary margin and gently pulled away. 
Finally, the choroid and ciliary body were removed by grasping the choroid 
close to the ora serrata and gently pulling it along with the ciliary body away 
from the underlying sclera. The anterior segment was then placed in culture 
medium and stored chilled until the time of perfusion.
Perfusion technique: The corneoscleral shell with attached outflow tissue was 
mounted onto a specialised perfusion apparatus (Figure 111) and perfused at 
15mmHg with culture medium (Dulbecco’s Modified Eagle’s Medium; Sigma
88
Chemical Co, St Louis, MO, USA) with added antibiotics (penicillin; 
50 U .m H , streptomycin 50pg.ml“l; fungizone [amphotericin] 5pg.ml”l; all 
from Sigma Chemical Co) (DMEM + PSF) at 37°C in a 5% CO2 environment. 
Under these conditions, the tissue remains viable for up to one week. Outflow 
facility was calculated as the ratio of the measured flow of culture medium into 
the chamber to the perfusion pressure: = f/P  (pLmin“l. mmHg'l). All
determinations of outflow facility consisted of an average of 4-5 consecutive 5- 
min facility determinations, commencing when the rate o f fluid flow into the 
perfusion chamber had reached steady state (usually 20 - 30 min after onset of 
perfusion).
3.3.1 Assessment of the effect of Healon vs a sham injection on
outflow facility (pilot study)
In a pilot study the effect of Healon vs a sham injection on outflow facility was 
assessed in a pair of human eyes (74-year old female). In this experiment after 
establishment of a baseline outflow facility in both eyes, the perfusion 
chambers were emptied. In the experimental eye the perfusion chamber' was 
filled with 300pl of Healon via an injection with a 27G needle at the limbus 
and outflow facility measurements continued for 3h. In the contralateral eye 
the perfusion chamber was filled with 3 00pi of culture medium (DMEM + 
PSF) and outflow facility measurements resumed for the same period of time.
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Figure 11 A: The perfusion apparatus. B: Diagrammatic representatim off 
the perfused human ocular anterior segment model. For the sake of chrity,, 
one of three clamping posts was omitted from the diagram (Erickson-Lamy' 
et_al, 1991).
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3.3.2 Assessment of the effect of different dilutions of Healon on
outflow facility
After establishment of a baseline outflow facility, the chamber contents 
of 20 eyes were emptied and the chamber was refilled with 300pl of 3 different 
concentrations of Healon (100%, 50%, 10%). The 50% and 10% 
concentrations of Healon were prepared from the commercial product 
containing sodium hyaluronate (1%) by thorough vortex mixing with culture 
medium (DMEM + PSF) immediately prior to the injection. In some 
experiments, Healon was injected at the limbus using a 27G needle. In other 
experiments, Healon was injected through the outflow port of the perfusion 
apparatus. After Healon injection, outflow facility measurements resumed for 
3-24h. A paired comparison was made in each eye between pre-Healon 
baseline outflow facility and post-Healon outflow facility.
3.3.3 Assessment of the effect of ascorbate on the Healon-induced 
reduction in outflow facility
In these studies, the effect of a high constant concentration of ascorbate 
(lOOOpg.ml‘ 1) was assessed on the Healon- induced outflow facility reduction.
After establishment of a baseline outflow facility in 3 pairs of eyes (69, 
81 and 86-year old male donors) the perfusion chambers were emptied and 
300pi of Healon (50% dilution in culture medium) was injected through the 
outflow port of the perfusion apparatus in both eyes. In the experimental eye 
the perfusion was then carried out with added ascorbate (lOOOpg.ml"! in 
culture medium) and outflow facility was measured for 6h. In the
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contralateral control eye the perfusion was continued with culture medium 
without added ascorbate and outflow facility was measured for the same period 
of time.
Morphological examination of perfused outflow tissue: After perfusion with 
Healon with or without added ascorbate, anterior segments were fixed at 
perfusion pressure (15mmHg) with freshly prepared Kamovsky's fixative (4% 
glutaraldehyde, 5% paraformaldehyde, 0.1 M Na cacodylate, 0.5mg.ml'l 
CaCl2) for 30 min followed by immersion in 1% alcian blue in 3% acetic acid 
(pH 2.5). In the pair of human eyes of the pilot study, alcian blue was not 
used. Tissue was processed for light microscopy according to standard 
protocols and morphological examination was carried out.
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CHAPTER 4 
RESULTS
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4.1 THE EFFECT OF HEALON ON POSTOPERATIVE IOP
FOLLOWING CATARACT SURGERY (Specific aim A .l)
The results of postoperative IOP, measured 6 and 24h after ECCE with 
p/c IOL in patients who received or did not receive Healon are shown in Table 
7 (top half). In this study, Healon-treated eyes were further subdivided into 
different groups based on the volume of Healon used intraoperatively: <0.2ml 
Healon, 0.2-0.35ml Healon and >0.35ml Healon (Table 7, bottom half). There 
was no statistically significant difference between age and sex among groups. 
These data show that the initial IOP was not different between the operated 
and contralateral control eye preoperatively in all groups. Six hours after 
surgery there was a significant increase in IOP in the operated eyes of all 
groups except for the group receiving <0.2ml Healon, with the 0.2 - 0.35ml 
group having a mean difference of about 7mmHg, similar to the no Healon 
group, and the > 0.35ml group having an average difference of about 17mmHg. 
At 24h there were no large differences in IOP between operated and control 
eyes in any of the groups. However, there was a statistically significant 
average elevation o f 3mmHg in the operated eye relative to the control eye in 
the >0.35ml Healon group.
Although on the average IOP was not greater 6h postoperatively in the 
<0.2ml Healon group, the pressure differences between operated and control 
eyes ranged from the operated eye having a pressure o f lOmmHg less than to 
12mmHg greater than the fellow control eye. Pressure differences at 6h ranged 
from -1 to 17mmHg, -5 to 36mHg and -4 to 37mmHg in the no Healon, 0.2- 
0.35ml Healon and >0.35ml Healon groups, respectively (Table 7).
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Table 8 shows the significance of difference in IOP between operated and 
control eyes among no Healon- and Healon-treated (in whatever volume) eyes 
at 6 and 24h postoperatively.
Comparisons among the different treatment groups showed that the IOP 
difference between operated and contralateral control eyes at 6h 
postoperatively was significantly higher in the >0.35ml Healon group than in 
all other groups. Interestingly, the IOP difference was significantly less in the 
<0.2ml group than in either of the groups treated with larger volumes of 
Healon, but although lower not from eyes receiving no Healon (Table 9 and 
Figures 12 and 13).
Table 10 shows the incidence of difference in IOP greater than lOmmHg 
between operated and contralateral control eyes among patients who received 
various volumes of Healon during cataract surgery. The significance of these 
incidences of differences at 6h postoperatively are presented in Table 11. 
These tables show that a significantly higher percentage of patients (77%) who 
received >0.35ml Healon exhibited difference in IOP greater than lOmmHg 
between operated and control eyes at 6h postoperatively as compared with that 
of 35%, 10% and 42% in the no Healon, <0.2ml Healon and 0.2-0.35ml 
Healon groups, respectively. At 24h, there was still a high percentage of 
patients (22%) in the >0.35ml Healon group with a difference in IOP greater 
than lOmmHg. However, in all other groups IOP returned to preoperative 
levels.
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Figure 12 Differences in IOP between operated and control eyes following 
the use of various volumes of Healon during cataract surgery 6h 
postoperatively.
Graphical representation of data in Table 7, column 6 showing the difference 
(O-C) in IOP between operated (O) and control (C) eyes at 6h after cataract 
removal. The differences are shown in relation to the volume of Healon used 
during the operation. Patient numbers in each group are indicated within the 
blocks. Statistical significance of the difference (determined by the two- tailed 
unpaired t-test) between eyes receiving >0.35ml Healon and those which did 
not: ***p<0.001; between >0.35ml and <0.2ml Healon treatment:
***p<0.001; between >0.35ml and 0.2-0.35ml Healon treatment: ++p<0.01; 
between 0.2-0.35ml and <0.2ml Healon treatment: +p<0.05. Similar statistical 
significance was also revealed by the non-parametric (distribution-free) Mann- 
Whitney U test.
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Figure 13 Differences in IOP between operated and control eyes following 
the use of various volumes of Healon during cataract surgery 24h 
postoperatively.
Graphical representation of data in Table 7, column 6 showing the difference 
(O-C) in IOP between operated (O) and control (C) eyes at 24h after cataract 
removal. The differences are shown in relation to the volume of Healon used 
during the operation. Patient numbers in each group are indicated within the 
blocks. Statistical significance of the difference (determined by the two- tailed 
unpaired t-test) between eyes receiving >0.35ml Healon and those which did 
not: **p<0.01; between >0.35ml and <0.2ml Healon treatment: **p<0.01; 
between >0.35ml and 0.2-0.35ml Healon treatment: +p<0.05. Similar statisti­
cal significance was also revealed by the non-parametric (distribution-free) 
Mann-Whitney U test.
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TABLE 8: SIGNIFICANCE OF DIFFERENCES IN IOP
BETW EEN OPERATED AND CONTROL EYES AM ONG 
NO HEALON- AND HEALON-TREATED PATIENTS
Group Compared P
A. At 6h after sureerv
Healon vs No Healon 0.08
B. At 24h after sureerv
Healon vs No Healon 0.07
The difference in IOP between operated and fellow control eyes 6h and 24h 
postoperatively was compared among patients who did not receive Healon and 
all those who received Healon (in whatever volume) intraoperatively. 
Statistical significance (p) of these differences was determined by the two- 
tailed unpaired t-test. Similar statistical significance was also revealed by the 
non- parametric (distribution-free) Mann-Whitney U test.
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TABLE 9: SIGNIFICANCE OF DIFFERENCES IN IOP BETWEEN 
OPERATED AND CONTROL EYES AMONG PATIENTS 
RECEIVING VARIOUS VOLUMES OF HEALON 
INTRAOPERATIVELY
Groups Compared p
A. At 6h after surgery
Healon >0.35ml vs No Healon <0.001
Healon >0.35ml vs Healon <0.2ml <0.001
Healon >0.35ml vs Healon 0.2 - 0.35ml <0.01
Healon 0.2-0.35ml vs No Healon ns
Healon 0.2-0.35ml vs Healon <0.2ml <0.05
Healon <0.2ml vs No Healon ns
B. At 24h after surgery
Healon >0.35ml vs No Healon <0.01
Healon >0.35ml vs Healon <0.2ml <0.01
Healon >0.35ml vs Healon 0.2-0.35ml <0.05
Healon 0.2-0.35ml vs No Healon ns
Healon 0.2-0.35ml vs Healon <0.2ml ns
Healon <0.2ml vs No Healon ns
The difference in IOP between operated and fellow control eyes 6h and 24h 
postoperatively was compared among groups of patients receiving stated 
volumes of Healon intraoperatively. Statistical significance (p) of these 
differences was determined by the two-tailed unpaired t- test. Similar statistical 
significance was also revealed by the non-parametric (distribution-free) Mann- 
Whitney U test.
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TABLE 10: INCIDENCE OF DIFERENCES IN IOP GREATER
THAN lOmmHg BETWEEN OPERATED AND 
CONTROL EYES AMONG PATIENTS RECEIVING  
VARIOUS VOLUMES OF HEALON 
INTRAOPERATIVELY
Time
(h)
Volume of 
Healon (ml)
No of 
Patients
No of patients with 
AIOP >10mmHg Percentage
0 20 7 35
<0.2 10 1 10
6 0.2-0.35 19 8 42
>0.35 27 21 77
0 20 0 0
<0.2 10 0 0
24 0.2-0.35 19 0 0
>0.35 27 6 22
IOP measurements were taken at 6h and 24h after cataract removal in human 
eyes which received the stated volume of Healon intraoperatively. Column 3 
shows the total number of patients in each treatment group and column 4 
shows the number of patients with differences in IOP greater than lOmmHg 
between operated and contralateral control eyes.
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TABLE 11: SIGNIFICANCE OF INCIDENCE OF IOP DIFFERENCES 
GREATER THAN lOmmHg BETWEEN OPERATED AND 
CONTROL EYES 6h POSTOPERATIVELY AMONG 
PATIENTS RECEIVING VARIOUS VOLUMES OF 
HEALON
Groups Compared P
Healon >0.35ml vs No Healon <0.01
Healon >0.35ml vs Healon <0.2ml <0.01
Healon >0.35ml vs Healon 0.2-0.35ml <0.05
Healon 0.2-0.35ml vs No Healon ns
Healon 0.2-0.35ml vs Healon <0.2ml 0.07
Healon <0.2ml vs No Healon ns
Statistical significance (p) of these incidences was determined by the chi- 
squared test.
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4.2 THE EFFECT OF HEALON ON OUTFLOW FACILITY IN THE
HUMAN EYE IN VITRO (Specific aim A.2)
A pilot study designed to assess the effect of Healon vs a sham injection 
on outflow facility was conducted in one pair of human eyes and the results are 
presented in Figure 14. This Figure shows that the injection of Healon resulted 
in an average reduction in outflow facility of 64% over a period of 3h when 
compared with baseline. The contralateral eye which underwent a sham 
injection of culture medium showed a modest increase in outflow facility over 
the same period of time.
The result of this study is consistent with the histological findings 
reported by an independent ocular pathologist (Professor WR Lee, Western 
Infirmary, Glasgow): "In the eye which was not exposed to Healon, there is 
some outward movement of the uveal and corneoscleral layers and giant 
vacuoles are present in Schlemm's canal where the canal remains open. In the 
Healon perfused tissue, there is more displacement of the meshwork and the 
canal of Schlemm is much narrower. Giant vacuoles are not seen in significant 
numbers in the Healon perfused system. It would appear from this material 
that the Healon is lying on the inner surface of the meshwork and the pressure 
is forcing the various layers of the meshwork out against the scleral sulcus" 
(Figures 15A and 15B).
Table 12 shows the results of a study designed to assess the effect of 
different dilutions of Healon on outflow facility. This table shows that Healon 
substantially decreases outflow facility in the human eye in a concentration- 
related fashion at levels lower (ie, 50% and 10%) than the commercial 
preparation used in intraocular surgery.
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The maximum obstruction studied over a period of up to 24h was 55%, 
30% and 12% for the 100% (undiluted), 50% and 10% Healon dilution, 
respectively. This maximum obstruction typically lasted for at least lh  and in 
cases of higher concentrations of Healon (ie, 50% and undiluted) up to 6h or 
more.
In some instances, the obstruction was apparent immediately after the 
instillation of Healon or diluted Healon into the perfusion chamber. In other 
cases, there was a delay of up to 6h before the maximum obstruction became 
apparent. All eyes which received Healon and most eyes at the lower 
concentrations exhibited at least some degree of obstruction. However, in four 
eyes (two receiving 10% and two receiving 50% dilution) no obstruction was 
noted and, in fact, the outflow facility modestly increased.
A typical graphical representation of the reduction in outflow facility 
following the injection of Healon (50% dilution) is presented in Figure 16. 
The histological findings of this eye are shown in Figure 17.
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Figure 14 The effect of Healon vs a sham injection on outflow facility in 
the human eye in vitro.
Anterior segments from a pair of human eyes (74-year old female) were 
perfused with culture medium at 15mmHg at 37°C in a 5% CO2 environment 
as described in Materials and Methods. After ninety minutes of perfusion 
(arrow) the perfusion chamber was emptied and refilled with 300^1 of Healon 
or culture medium via an injection with a 27G needle at the limbus. Data show 
that Healon progressively and substantially reduces outflow facility over a 
period of 3h, while the sham injection results in a modest increase in outflow 
facility.
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Figure 15A Light micrograph of a human eye perfused with culture 
medium. Semithin section of the trabecular meshwork of the eye (74-year 
old female) perfused with culture medium. Both the uveal (U) and 
corneoscleral (C) layers are open with large intertrabecular spaces (I). 
Schlemm's canal (SC) is open and a number of giant vacuoles (arrowheads) 
can be seen lining the cribriform layer. Toluidine blue, x630.
Figure 15B Light micrograph of a human eye perfused with Healon.
Semithin section of the trabecular meshwork from the fellow eye of the 
same donor as in Figure 15A perfused with Healon. There is considerable 
compression of the corneoscleral layer, indicated by decrease in size of the 
intertrabecular spaces (I), Schlemm's canal (SC) is much narrower than the 
control eye and giant vacuoles are absent. Toluidine blue, x630.
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TABLE 12: THE EFFECT OF DIFFERENT DILUTIONS OF 
HEALON ON OUTFLOW FACILITY IN THE 
HUMAN EYE IN VITRO
% Healon n C0 Ch cH/c0
100 3 0.20±0.05 0.07±0.01 0.45±0.15c
50 12 0.21±0.03 0.13±0.02 0.70±0.11a
10 5 0.22±0.04 0.17±0.04 0.88±0.25b
Anterior segments of human eyes were perfused with culture medium at a 
pressure of 15mmHg at 37°C in a 5% CO2 environment as described in 
Materials and Methods. After establishment of a baseline outflow facility 
(C0), the perfusion chamber was emptied and refilled with 3 00pi of the 
indicated dilutions of Healon either through an injection with a 27G needle at 
the limbus or through the outflow port of the perfusion apparatus, and outflow 
facility measurements resumed. Cjj represents the maximum amount of 
obstruction obtained after Healon injection over a period of up to 24h. For 
each eye, the ratios (Cj-[/C0) were calculated first and then the means. Data 
shown are means ± SEM for the indicated number (n) of eyes. Outflow 
facility is expressed as pl.min"l.mmHg"l. Cjj/Cq is significantly different 
from 1.0 by the two- tailed paired t-test (ap < 0.001, &p <0.05, cp <0.1).
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Figure 16. The effect of Healon (50% dilution) on outflow facility in the 
human eye in vitro.
An anterior segment from a human eye (81-year old female) was perfused with 
culture medium at 15mmHg at 37°C in a 5% CO2 environment as described in 
Materials and Methods. After ninety minutes of perfusion (arrow) the 
perfusion chamber was emptied and refilled with 300pl of Healon (50% 
dilution) via the outflow port of the apparatus. Data show that Healon (50% 
dilutuion) substantially reduces outflow facility for at least 6h post-injection
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Figure 17
Light micrograph of a human eye perfused with Healon (50% dilution).
Semithin section of the trabecular meshwork of an eye (81-year old female) 
after a 6h perfusion with Healon (50% dilution). Fixation with Kamovsky's 
fixative followed by immersion in alcian blue was carried out as described in 
Materials and Methods. The Healon (arrowed) is located at the junction 
between the uveal layer (U) and the anterior chamber (AC). Note the absence 
of Healon from the corneoscleral layer (C), the cribriform layer and Schlemm's 
canal (SC). Both the uveal and corneoscleral layers are compressed and 
Schlemm's canal is collapsed. Toluidine blue, x630.
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4.3 THE EFFECT OF SURGERY AND HEALON ON
POSTOPERATIVE ASCORBATE CONCENTRATION IN THE 
RABBIT AQUEOUS HUMOUR (Specific aim B .l)
The effect of surgery (corneal incision alone) on aqueous ascorbate 
levels was studied in the rabbit eye in vivo in two series of experiments. In 
the first set of experiments, aqueous samples were taken at 6, 12, 24, and 48h 
after an initial comeal incision was made at time zero in 7 rabbits. These data 
show that there is a substantial drop in aqueous ascorbate levels during the first 
24h postoperatively with a slight recovery at 48h (Figure 18, top). In a second 
series of experiments in 7 rabbits at slightly different timepoints (2, 5, 8, 24, 
48h) the results were similar (Figure 18, bottom). In these experiments, at 24h 
the ascorbate levels dropped to an average of 45% of the zero-time value with a 
recovery to about 54% at 48h (Table 13). Comparison of fellow control eye at 
48h with the experimental eyes at time zero shows that the ascorbate levels 
were approximately 30% higher in the control eyes than the baseline levels in 
the experimental eyes (Table 13). Therefore, at 48h, there was a net decrease 
in ascorbate levels of 57% when comparing the experimental eye after multiple 
paracenteses with the fellow control eye (Table 13).
A similar effect on ascorbate levels was observed at 48h when a comeal 
incision alone was made at time zero where a decrease of 54% was observed, 
relative to the contralateral control eye (Table 14A). Lens removal did not 
appear to further compromise the ascorbate levels at 48h where a 56% decrease 
in ascorbate levels relative to the control eye was observed (Table 14A). 
Collectively, these data indicate that a considerable decrease in aqueous 
humour ascorbate concentration occurs in the early postoperative period and
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that additional lens removal does not further compromise the levels of 
ascorbate.
Figure 19 shows that plasma ascorbate levels following oral 
administration of 50mg/Kg body weight of ascorbic acid peaks within 2-3h and 
remains high for about 9-1 Oh.
The results after pretreating rabbits with systemic ascorbate (a single oral 
dose of 50mg/kg body weight, 3h preoperatively), show that, although initial 
levels of aqueous humour ascorbate werej significantly higher at time zero as 
compared with unloaded animals, pretreatment did not appear to enhance 
aqueous ascorbate at 6h and 48h (Tables 14A and 14B).
The intraoperative use of Healon did appear to influence ascorbate levels. 
There was a small (8%) (but not statistically significant) attenuation of the loss 
of ascorbate when intraoperative Healon was used in eyes which received 
comeal incision alone without lens removal (Table 14A). However, the use of 
Healon intraoperatively with lens removal resulted in dramatic reduction in the 
recovery of ascorbate levels. In this instance, ascorbate levels were only 26% 
of contralateral control at 48h, ie, there was an 18% increase in the loss of 
ascorbate as compared with eyes which did not receive Healon (Table 14A). 
The significance of the above differences in ascorbate levels is presented in 
Table 15.
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Figure 18 Timecourse of the effect of surgery on rabbit aqueous humour 
ascorbate concentration.
Aqueous humour ascorbic acid levels were measured in the rabbit eye in vivo 
in two series of experiments during the early postoperative period. In the first 
set of experiments (top) aqueous humour samples were taken at the indicated 
timepoints after an initial corneal incision at time zero in 7 rabbits. In the 
second set of experiments (bottom) aqueous humour samples were taken at 
slightly different timepoints as indicated. Data are the mean ascorbate 
concentrations in pg.ml“l and vertical bars show the SEM.
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TABLE 13: ASCORBATE LEVELS IN RABBIT AQUEOUS
HUMOUR FOLLOW ING CORNEAL INCISION AND 
SUBSEQUENT REPEATED PARACENTESES
Ascorbate (iig.ml-!)
Time(h) n Experimental
0 13 283±32
2 7 92±27
5 7 109±17
6 7 23±72
8 6 105±23
12 7 172±27
24 13 117±16
48 11 148±28
2/0 6 0.44±0.12*
5/0 6 0.58±0.09**
6/0 7 0.60±0.15**
8/0 5 0.52±0.13*
12/0 7 0.56±0.09**
24/0 12 0.45±0.05***
48/0 11 0.54±0.09***
Control/0
n Control n E/C
14 333 11 0.43±0.05***
13 1.30±0.15***
Ascorbate levels (mean ± SEM) in aqueous humour samples from rabbit eyes 
were measured after an initial corneal incision (0) and subsequent repeated 
paracenteses at the hours indicated. Ascorbate levels were measured in the 
fellow control eye at 48h intervals with no prior surgery. Eye numbers in each 
group are indicated (n).
Data for 0,24 and 48h are combined means from both series of experiments. 
Ratios are shown for ascorbate levels at each time interval relative to the zero­
time value (2/0, 5/0, 6/0, 12/0, 24/0, 48/0), as well as in the experimental eye 
relative to control eye at 48h (E/C) and control eye relative to zero-time value 
in the experimental eye (Control/0). These ratios are significantly different 
from 1.0 by the two-tailed paired t-test (*p <0.05; **p <0.01; ***p <0.001).
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TABLE 14A: ASCORBATE LEVELS IN RABBIT AQUEOUS HUMOUR
AFTER CORNEAL INCISION WITH AND WITHOUT 
LENS REMOVAL (WITH AND WITHOUT 
INTRAOPERATIVE USE OF HEALON)
Ascorbate (pg.ml‘1)
Group n Oh 6h 48h control 6h/Oh E/C
Corneal incision 
alone/no Healon 
Comeal incision 
alone/Healon
Comeal incision 
+ lens removal 
/no Healon 
Comeal incision 
+ lens removal 
/Healon
Comeal incision 
+ lens removal 
/ Healon + ascorl 
pretreatment 
Comeal incision 
+ lens removal 
/Healon
Ascorbate levels (mean ± SEM) were measured in the aqueous humour of 
rabbit eyes with or without pretreatment with ascorbate (50mg/kg body weight, 
3h preoperatively) after an initial comeal incision (Oh) with or without lens 
removal and subsequent paracentesis at the time(s) shown. Eye numbers in 
each group are indicated (n). In some groups, Healon was injected during the 
surgical procedure. Ascorbate levels were measured in the fellow control eye 
at 48h. Ratios of ascorbate levels in experimental eyes compared to control 
eyes at 48h (E/C) and in experimental eyes compared to zero time (6h/Oh) are 
significantly different from 1.0 by the two-tailed paired t-test (*p <0.001).
5 248±38 189=1=36 433±96 0.46±0.04*
5 219±19 110±15 206=1=24 0.54±0.05*
6 237±26 91±13 204±22 0.44±0.02*
6 396±85 123=1=30 458±76 0.26±0.03*
bate
5 613=1=95 148±22 78±19 218±73 0.25=1=0.03*
4 436±29 138=1=51 84±38 379±33 0.29±0.09*
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TABLE 14B: THE EFFECT OF ASCORBATE PRETREATMENT 
ON THE CONCENTRATION OF ASCORBATE IN 
RABBIT AQUEOUS HUMOUR
n Oh
Ascorbate pretreatment 5 613±95*
No ascorbate pretreatment 26 297±26
This Table shows combined data from Table 14A. Ascorbate levels (mean ± 
SEM) were measured in the aqueous humour of rabbit eyes with and without 
pretreatment with ascorbate (50mg/kg body weight, 3h preoperatively) after an 
initial corneal incision (Oh). Eye numbers in each group are indicted (n). The 
difference in aqueous humour ascorbate levels between pretreated and non­
pretreated rabbit eyes are significantly different from zero by the two-tailed 
impaired t-test (*p<0.05).
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TABLE 15: SIGNIFICANCE OF DIFFERENCES IN
ASCORBATE LEVELS IN RABBIT AQUEOUS 
HUMOUR AFTER CORNEAL INCISION 
WITH AND WITHOUT LENS 
REMOVAL (WITH AND WITHOUT 
INTRAOPERATIVE USE OF HEALON)
Groups Compared p
Corneal incision only
No Healon vs Healon
Corneal incision + 
lens removal
No Healon vs Healon
j
I Corneal incision +
i lens removal vs corneal
incision
Healoni
No Healon
The difference in ascorbate levels between operated (corneal incision only or 
corneal incision and lens removal) and control eyes 48h postoperatively was 
compared among groups of rabbit eyes receiving Healon or no Healon 
intraoperatively. Statistical significance (p) was determined by the two-tailed 
unpaired t-test.
ns
< 0.01
<0.01
ns
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Figure 19 Timecourse of rabbit plasma ascorbate levels following a single 
oral dose (50mg/kg body weight) of ascorbate.
Seven rabbits received orally 50mg/kg body weight of ascorbate at time zero 
(arrow) and blood samples were obtained for ascorbate analysis at the 
indicated timepoints. Data are the mean ascorbate concentrations in pg.ml- ! 
and vertical bars show the SEM.
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4.4 THE EFFECT OF SYSTEMIC ASCORBATE PRETREATMENT
ON AQUEOUS HUMOUR ASCORBATE LEVELS IN THE
HUMAN EYE (Specific aim B.2)
The results of a pilot study designed to determine the timecourse of 
plasma ascorbate levels following ingestion of a single lg dose of ascorbate are 
presented in Figure 20. This Figure shows that plasma ascorbate levels peak 
within 2-4h, remain high for 3-5h and fall to the preloaded concentration about 
lOh after the ingestion.
Figures 21A and 2 IB show the aqueous humour and plasma ascorbate 
levels respectively in cataract patients receiving no ascorbate or a total dose of 
1, 2, 3 or 5g oral ascorbate in two equal doses, administered the evening before 
surgery and the morning of surgery. Aqueous humour ascorbate levels 
(pg.ml"l) measured in this study ranged from 80 to 518 (266±14), 110 to 509 
(268±41), 194 to 1066 (643±73), 207 to 1956 (655±96) and 497 to 798 
(649±86; mean±SEM) for the 0, 1, 2, 3 and 5g group, respectively.
Plasma ascorbate levels (pg.ml“l) ranged from 1.2 to 11.1 (5.1±1.1), 5.2 
to 15.9 (8.7±0.9), 6.8 to 22.9 (13.6±1.8), 15.7 to 45.9 (27.7±4.2) and 42.6 to 
103.3 (72±12.4; mean ± SEM) for the 0, 1, 2, 3 and 5g group, respectively.
These results show that plasma ascorbate increased with each incremental 
dose, the lg  dose of ascorbate producing approximately double the normal 
level. Aqueous ascorbate increased to a much lower extent than did plasma, 
with no significant further increase on administration of the 3 or 5g total dose. 
These data show that the maximal aqueous humour levels are attained after a 
total dose of 2g of ascorbate, representing an approximate two-fold increase 
over non-pretreated patients. Further regression analysis did not reveal any 
correlation between aqueous humour ascorbate levels and age or sex of the 
patients in any of the groups.
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Figure 20 Timecourse of human plasma ascorbate levels following oral 
administration of a single lg  dose of ascorbate.
Five adult volunteers received lg of ascorbate orally at time zero (arrow) and 
blood samples were obtained for ascorbate analysis at the indicated timepoints. 
Data are the mean ascorbate concentrations in pg.m H  and vertical bars show 
the SEM.
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Figure 21A Human aqueous humour ascorbate levels following systemic 
ascorbate pretreatment.
Aqueous humour ascorbate levels were measured in cataract patients receiving 
no ascorbate or a total dose of 1, 2, 3 or 5g oral ascorbate preoperatively as 
described in Materials and Methods. Patient numbers in each group are 
indicated within the blocks. Data are the mean ascorbate concentrations in 
pg.ml“l and vertical bars show the SEM. The difference in ascorbate level 
between patients pretreated with 2, 3 or 5g total dose and those who did not 
receive ascorbate is significantly different from zero by the two-tailed unpaired 
t-test: (*** p<0.001; * p<0.05).
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Figure 21B Human plasma ascorbate levels following systemic ascorbate 
pretreatm ent.
Plasma ascorbate levels were measured in cataract patients receiving no 
ascorbate or a total dose of 1, 2, 3 or 5g oral ascorbate preoperatively as 
described in Materials and Methods. Patient numbers are indicated within the 
blocks. Data are the mean ascorbate concentrations in pg.ml“l and vertical 
bars show the SEM. The difference in ascorbate levels between patients 
pretreated with 1,2, 3 or 5g total dose and those who did not receive ascorbate 
is significantly different from zero by the two-tailed unpaired t-test:
(*p<0.001).
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4.5 THE EFFECT OF ASCORBATE ON THE HEALON-
INDUCED REDUCTION IN OUTFLOW FACILITY IN THE
HUMAN EYE IN VITRO (Specific aim B.3).
Table 16 shows the results of a study which assessed the effect of a high 
constant concentration of ascorbate on the Healon-induced reduction in 
outflow facility in human eyes in vitro.
Although this was a small study,these data show that the Healon-induced 
reduction in outflow facility did not improve in the presence of a high 
(1000pg.ml"l) constant concentration of ascorbic acid over a period of 6h. In 
fact, a paired comparison shows a higher degree of maximum obstruction 
observed in the presence of ascorbate as compared with contralateral control 
(pairs 1 and 2). In pair 3, although the outflow facility in the presence of 
ascorbate was modestly improved as compared with control, a substantial 
amount of obstruction still remained (25%) in this eye.
Histological examination did not reveal any difference between ascorbate 
and non-ascorbate treated eyes and the findings were similar to those presented 
in Figure 17.
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TABLE 16: THE EFFECT OF ASCORBATE ON THE HEALON- 
INDUCED REDUCTION IN OUTFLOW FACILITY
CH+A CH Cn+A/Ce CH/Cc CH+A/Ce
cH/cc
Pair 1 0.13 - 0.04 - 0.31 - q.39
0.28 - 0.22 - 0.78
Pair 2 023 - 007 - °-30 - 0.79
0.29 - 0.11 - 0.38
Pair 3 0 24 “ 0 18 - 0 75 - 1.5
0.30 - 0.15 - 0.5
Anterior segments of 3 pairs of human eyes were perfused at a pressure of 
15mmHg with culture medium at 37°C in a 5% CO2 environment as 
described in Materials and Methods. After establishment of a baseline 
outflow facility (Ce for the experimental eye and Cc for the control eye), the 
perfusion chambers were emptied and Healon (50% dilution in culture 
medium) was injected in both eyes through the outflow port of the perfusion 
apparatus. In the experimental eye, the perfusion continued with added 
ascorbate (1000 pg.ml'l in culture medium) while the contralateral control 
eye was perfused with culture medium with no added ascorbate, and 
subsequent outflow facility determinations were made. Cjj+A Cp[ 
represent the maximum amount of obstruction obtained after Healon injection 
in the experimental and control eyes respectively (expressed as pl.min- !. 
mmHg‘ 1), over a period of 6h. Data in columns 6 and 7 show comparisons of 
post-Healon outflow facility over baseline (Cjj+A/Ce and C h/C c) in the 
experimental and control eyes, respectively. Paired comparisons of these 
Cn+A/Ce ^  Presented in column 8.
c H/ c c
123
4.6 THE EFFECT OF SYSTEMIC ASCORBATE PRETREATMENT
ON POSTOPERATIVE IOP FOLLOWING CATARACT 
SURGERY WITH INTRAOPERATIVE USE OF HEALON 
Specific aim B.4)
A comparison of the IOP measurements among groups of cataract 
patients receiving Healon with and without pretreatment with a total dose of 2g 
of oral ascorbate shows that ascorbate administration did not influence the 
early (6h and 24h) postoperative rise in IOP (Table 17).
Further, regression analysis did not reveal any correlation between 
aqueous humour ascorbate levels at the time of surgery and postoperative rise 
in IOP in any of the Healon groups.
Further, two-way analysis of variance did not indicate any effect of 
ascorbate pretreatment on postoperative IOP rise in any of the Healon groups.
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CHAPTER 5 
DISCUSSION
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5.1 DISCUSSION OF THE STUDY
The original reports on the use of Healon during cataract surgery did not 
mention any postoperative IOP elevation. In several studies no statistically 
significant differences in IOP were observed after use of Healon compared 
with controls (Pape and Balazs, 1980; Miller and Stegmann, 1981; Stegmann 
and Miller, 1982; Holmberg and Philipson, 1984a, 1984b). Other studies 
showed significant elevations in postoperative IOP following the use of Healon 
and advocated irrigation and aspiration of Healon at the end of surgery (Pape, 
1980; Lazenby and Broocker, 1981; Olivius and Thorbum, 1985). Subsequent 
studies described that despite irrigating/aspirating Healon at the end of surgery, 
significant postoperative IOP rises occurred (McGuigan et_al, 1986; Ruiz et ah 
1987). However, a too vigorous attempt to irrigate/aspirate the Healon at the 
end of surgery should be avoided as a potential damage to the corneal 
endothelium may occur (Olivius and Thorbum, 1985).
The exacerbating effect of Healon use on the immediate postoperative 
IOP elevation after cataract surgery has been described by a number of authors 
in more recent studies. The maximal IOP increase has been reported to occur 
within 6h (Cherfan et ah 1983; Barron et ah 1985; Naeser et al. 1986; 
Anmarkrud et al, 1992), 12h (Ruusuvaara et ah 1990) or 16h (Passo et al.
1985) postoperatively and returns to baseline levels within 24- 48h. The 
results of the present study are consistent with these previous observations.
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In the present study (where the Healon-treated patients were also 
subdivided in three different groups according to the volume of Healon used 
intraoperatively), patients' IOP was significantly higher in eyes which received 
Healon in amounts larger than 0.35 ml when compared with operated eyes 
which did not receive Healon. The pressure elevations were evident by 6h 
postoperatively and with the exception of eyes which received more than 0.35 
ml Healon, IOP returned to preoperative levels by 24h (Table 7). These IOP 
elevations occurred despite an attempt to remove by aspiration or irrigation 
the remaining Healon at the end of the procedure which has been 
recommended by many authors (Pape, 1980; Lazenby and Broocker, 1981; 
Miller and Stegmann, 1981, 1982; Hoffer, 1982; Stegmann and Miller, 1982; 
Cherfan et ah 1983; Glasser et al. 1986; Calissendorff and Hamberg-Nystrom, 
1993) in order to prevent or attenuate postoperative increases in IOP.
The dose-dependence of the postoperative Healon-induced IOP elevations
has not been systematically addressed in previous studies. Polack et al
(1981) and Polack (1982, 1986) have, however, shown that in keratoplasty 
with or without IOL implantation, IOP elevation occurs only when more than 
0.4 ml Healon is injected into the anterior chamber. These authors concluded 
that IOP elevation may be dose-dependent. The results of the present study 
suggest that there is a Healon dose-dependence of both the magnitude and 
duration of the postoperative IOP elevation.
The clinical trial showing this effect as described in this thesis was 
constrained by a number of limitations:
a) it was not possible to mask the use and the injected volume of Healon for
every case.
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b) it was neither practicable nor ethical to randomize the volume of Healon 
used in each operation.
c) it was thus impractical to match patients in different treatment groups 
with respect to age, sex and pathology (eg, the various type and grade- 
maturity of cataract).
d) there was no uniformity of surgical cataract extraction procedure 
(although all participated surgeons were experienced and ECCE with p/c 
IOL was performed in all cases in a similar fashion) nor of IOL type.
e) there was no uniformity in the procedure employed to wash Healon out of 
the eye (volume and direction of Hartmann's solution).
f) there was variation in the anaesthetic procedures employed, although 
similar percentages of each group underwent general and local 
anaesthesia
g) there was variation in diet, general pathology and medication among the 
patients.
However, despite these caveats, highly significant variations in IOP were 
observed with respect to the volumes of Healon used during the routine 
cataract surgery performed by five ophthalmic surgeons. The results have thus 
revealed a major potentially avoidable hazard.
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The results of this trial suggest that eyes which received less than 0.2ml 
do not show an elevation in postoperative IOP at 6h, those which receive 0.2- 
0.35 and greater than 0.35ml of Healon do, and in the latter case, higher IOP 
elevations are expected. Further, while IOP returns to preoperative levels at 
24h in all eyes receiving less than 0.35ml Healon, the pressure would still be 
elevated at 24h in eyes which receive greater than 0.35ml Healon.
The present study also suggest that potentially harmful high IOP spikes at 
6h postoperatively occur when more than 0.35ml of Healon is used 
intraoperatively (Tables 10 and 11).
The absence of an IOP increase in the eyes receiving less than 0.2ml 
Healon may have important implications for surgical procedures using Healon. 
While the results of this part of the study are based on a small population (ie, 
10 subjects) they suggest that the use of a small amount of Healon during 
cataract surgery may be adequate to ensure a good surgical outcome without 
raising IOP. It should be noted that the range of IOPs at 6h postoperatively in 
this group was from lOmmHg less than to 12mmHg greater than the fellow 
eye. Three out of the ten eyes in this group were hypotonic (ie. the IOP 
deficit from the fellow eye was 5mmHg or greater). However, there were no 
complications or remarkable clinical sequelae to the surgical procedures. 
Further, in this particular group, Healon was used only to deepen the anterior 
chamber and not for the reformation and expansion of the capsular bag.
The residual amount of Healon left in the eye varies with different 
extracapsular cataract extraction techniques. One study reported that the use of 
Healon in the "envelope-like" technique of cataract removal (as performed in 
the present study) clearly caused significantly greater postoperative elevations 
in IOP than the "can-opener" technique, as some Healon remains unavoidably
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in the capsular bag and "may obstruct mechanically the outflow channels or 
may shallow the anterior chamber" (Ruusuvaara et al, 1990). Another clinical 
study in a larger population is necessary to confirm conclusions based on these 
results.
More recent studies (Ohrstrom et a l  1989; Smith and Burt, 1991; Assia et 
aj, 1992) using sodium hyaluronate tinted with sodium fluorescein (Healon 
Yellow, Kabi Pharmacia, Uppsala, Sweden) during cataract surgery described 
that a considerable amount of Healon is inadvertently left in the eye, especially 
behind the IOL, despite an attempt to dilute and aspirate this highly viscous 
solution at the end of surgeiy. However, in these studies details of the type of 
extracapsular technique used are not included. Healon Yellow is not available 
in the UK yet, but it seems promising in order to study the amounts of Healon 
trapped behind the IOL and also to assess the dynamics of Healon removal at 
the end of intraocular surgery.
Although it is postulated that in most patients the transiently elevated IOP 
may have no adverse effect, there may be serious consequences of highly 
elevated IOP postoperatively, even in normal eyes without a compromised 
outflow system. Sustained elevations in IOP may result in optic neuropathy 
(glaucomatous or ischaemic), inhibition of wound healing, retinal vascular 
occlusion, severe pain or corneal oedema (Kolker, 1977; Hayreh, 1980; Bartov 
et a l  1984).
In the glaucomatous eye, modest and even transiently elevated IOP may 
be disastrous for the remaining visual field as additional and irreversible 
damage of the optic nerves may ensue (Kolker, 1977; Hayreh, 1980). IOP rises 
following cataract extraction have been reported to occur more frequently and 
to higher levels in eyes with preexisting glaucoma or exfoliation syndrome
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(Savage et al. 1985; McGuigan et al. 1986; Krupin et a l  1989; Ruusuvaara et 
al, 1990; Callissendorff and Hamberg- Nystrom, 1993).
The results of the present study suggest that if  Healon has to be used 
intraoperatively, a volume less than 0.2ml should be used in compromised 
eyes in order to prevent post operative IOP elevations. Further, the use of 
Healon for reforming the capsular bag before IOL insertion (which usually 
requires considerably more than 0.2ml Healon) is not recommended in high 
risk eyes (ie, glaucoma, exfoliation, ischaemic optic neuropathy).
The observation that IOP increases with Healon use during surgery even 
when attempts are made to remove Healon at the end of the procedure has led 
investigators to explore methods of attenuating the Healon-induced IOP 
elevation. Typically, beta blockers or other IOP lowering medications are 
administered in an attempt to block the Healon-induced IOP elevation 
(Haimann and Phelps, 1981; Miller and Stegmann, 1981, 1982; Percival, 1981, 
1982; Lewen and Insler, 1985; Wood, 1988; Linn et al. 1989; Anmarkrud et al. 
1992). However, the pre- or postoperative use of anti-glaucoma drugs is often 
ineffective or slow to take effect (Passo et a l 1985; Naeser et ah 1986; Ruiz et 
al, 1987). Therefore, a method of depolymerizing Healon in situ and thereby 
allowing its passage through the outflow pathways might attenuate post 
operative IOP rises.
Ascorbic acid at levels known to be present physiologically in the 
aqueous humour is known to depolymerize hyaluronic acid in vitro 
(Niedermeir et al, 1967; Wong et al, 1981; Motohashi et Mori, 1985; Fink and 
Lengfelder, 1987). This depolymerization appears to be concentration- 
dependent (Wong et al, 1981; Motohashi and Mori, 1985) at least for ascorbate 
levels up to l,000pM (176pg.ml"l). These observations suggest that raising
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aqueous humour levels of ascorbic acid or trying to maintain these levels high 
(as a fall is expected due to the damaging effect of surgery on the BAB) may 
aid in depolymerizing Healon and thus, preventing or attenuating Healon- 
induced increases in postoperative IOP.
Based on these in vitro observations, the feasibility of preloading the 
aqueous humour with ascorbate was explored as a method to depolymerize 
Healon and thereby to attenuate postoperative IOP elevations. In initial 
clinical studies, cataract patients were pretreated with oral ascorbate prior to 
surgery and aqueous humour ascorbate levels at the time of surgery were 
measured. These initial studies suggested that aqueous ascorbate levels could 
be increased to a maximum of about two-fold (Figure 21 A) following a 2g 
total dose over levels obtained in patients who were not pretreated.
The practicalities of theatre list arrangements prevented absolute accuracy 
in establishing a set interval between ascorbate ingestion and the start of 
cataract surgery. However, the present data on the timecourse of plasma 
ascorbate in plasma following oral administration of a single lg  dose show that 
absoiption is rather slow and the ascorbate concentration in plasma peaks 
within 2-4h, remains high for 3-5h and falls to the preloaded level about lOh 
after ingestion (Figure 20). These results are in good agreement with earlier 
determinations of peak plasma concentrations of ascorbate 3h after oral 
administration of a single lg dose (Yung et a l  1981; Melethil et al. 1986). 
These findings indicate that the interval (1 to 6h) between dosing on the 
morning of surgery and sampling of aqueous humour from cataract patients at 
the commencement of surgery was approximately correct. This was important 
in order to achieve a high and persistent level of plasma ascorbate, so that the 
ciliary body active transport system could best attain a high aqueous humour
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ascorbate level. It also suggests that the ingestion of a dose of ascorbate the 
night before surgery may be of relatively little additional value in boosting 
aqueous ascorbate concentration. Nevertheless, the night-and-moming 
regimen was adopted for the main clinical study, on the basis of the claim by 
Ringvold et al (1985) that this regimen is preferable to a single dose.
Plasma ascorbate is itself subject to considerable variation. Levels 
measured in the present work in untreated individuals ranged from 1.2 to 11.1 
pg.ml"! (5.1±1.1; mean ± SEM) which are similar to the value of 7±5.2 (mean 
± SD) determined by HPLC (Taylor et al. 1991).
Aqueous humour ascorbate levels were also variable in the present study, 
but corresponded closely to published values measured by HPLC (Ringvold et 
al, 1985; Taylor et a l  1991).
The results of the initial clinical study confirmed that increasing doses of 
ascorbate would increase the plasma ascorbate concentration almost linearly 
(Figure 2 IB) and showed that aqueous humour ascorbate levels can be 
increased by oral dosing with ascorbic acid. Oral dosing with more than 2g 
(total dose) did not lead to a further increase in the aqueous ascorbate levels 
(Figure 21 A). The probable explanation of this is that the ciliary body active 
transport system for ascorbate is approaching saturation and is therefore unable 
to utilise any further increase in plasma ascorbate concentration. The results of 
the present study are in good agreement with previously published human and 
animal studies (Kinsey, 1947; Linner, 1954; Becker, 1967; Reim et a l  1978; 
Giblin et a l  1984; Ringvold et a l  1985; Taylor et al. 1991) and confirm that 
the ascorbate transport system into the aqueous humour is saturable. However, 
the increased aqueous humour ascorbate levels did not influence postoperative 
IOP. While there was a direct correlation between the injected value of Healon
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and the postoperative IOP at 6 and 24h (Tables 7 and 9 and Figures 12 and 13), 
there was absolutely no correlation between aqueous humour ascorbate 
concentration at the time of surgery and postoperative IOP levels in any of the 
Healon groups (Table 17). Therefore, despite the strong evidence that 
hyaluronic acid can be depolymerized by ascorbic acid in vitro, this did not 
occur in vivo, or if it did, the depolymerization was not sufficient to reduce 
the Healon molecule to a size compatible with free clearance from the anterior 
chamber.
In order to better understand the failure of ascorbic acid pretreatment to 
prevent Healon-induced postoperative IOP elevation, measured 6 and 24h after 
cataract extraction,studies were conducted in the rabbit eye to determine 
whether the trauma of surgery may have been responsible for the absence of 
sufficient levels of ascorbic acid in the aqueous humour postoperatively. In 
these studies the effects of surgery (corneal incision alone and corneal incision 
plus lens removal) on aqueous humour ascorbate levels were determined. 
Some of the eyes also received intraoperative Healon.
Breakdown of the blood-aqueous barrier is a well known sequel of 
intraocular surgery (Sanders et a l  1982, 1983; Liesegang et a l  1984; Miyake 
et al, 1984a; Ferguson and Spalton, 1991). Clinical and rabbit studies also 
showed that residual Healon can contribute to and/or enhance the breakdown 
of the blood-aqueous barrier following intraocular surgery (Miyake and 
Mizuno, 1986; Machi et al. 1989; Tsurimaki and Shimizu, 1991a, 1991b).
The results of the present studies showed that in the first 2-6 hours 
postoperatively aqueous humour ascorbic acid levels were decreased to about 
half of the baseline levels (Table 13 and Figure 18) which persisted at 48h. 
This was true of eyes which received a corneal incision alone with or without
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added Healon (Table 14A), and also of eyes which underwent extracapsular 
lens extraction without added Healon. Interestingly, eyes which underwent 
extracapsular lens extraction with intraoperative Healon showed an additional 
statistically significant 18% drop in aqueous ascorbate relative to the 
contralateral control eyes at 48h (Tables 14A and 15). This result is 
presumably due to the damaging effect of Healon on the blood-aqueous barrier.
It is possible that during the intraoperative use of Healon residual lens 
debris is pushed out of the posterior chamber and may adhere to intraocular 
structures. In such a situation, where the presence of debris is prolonged, 
reactions may occur at the ciliary body, leading to release of mediators such as 
prostaglandins, which are well known to cause blood-aqueous barrier 
breakdown. (Unger et a l  1975; Eakins. 19771. Perhaps the intraoperative use 
of Healon is safer in cases of secondary IOL implantation in aphakic eyes 
where no lens material is present during the surgical procedure.
It is interesting to note that in the present work the ascorbate 
concentration in the contralateral eye was consistently greater by about 30%, 
48h after surgery, than in the experimental eye at the time of surgery (Table 
13).
Kottow and Seligman (1978) found that trauma induced by performing a 
limbal paracentesis consistently results in fluorescein leakage (indicating 
blood-aqueous barrier breakdown) in both the operated and contralateral eye. 
In a clinical study, Miyake et al (1984b) reported a consensual reaction of the 
blood-aqueous barrier in the contralateral eye following intraocular surgery.
The results of the present study suggest that in contradiction to the results 
of the aforementioned workers, the blood-aqueous barrier and associated 
membrane pumps were fully operational in the contralateral eye at this time.
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Alternatively, it is possible that if the blood-aqueous barrier did break down in 
the contralateral eye at an earlier timepoint, a compensatory mechanism was in 
place increasing the rate of transport of ascorbate into the anterior chamber. 
Further, recovery of the blood-aqueous barrier immediately after cataract 
surgery is perhaps more rapid in the primate, since Jampel et al (1992) found 
that ascorbic acid levels were unchanged in the monkey eye 24h after 
paracentesis.
After these initial experiments, an attempt was made to increase aqueous 
ascorbate levels by pretreating rabbits with oral ascorbate before surgery. 
Ascorbate pretreatment resulted in a moderate increase (about two-fold) in 
aqueous humour ascorbate levels at the time of surgery, which was statistically 
different from ascorbate levels after no pretreatment (Table 14B). Subsequent 
measurements 6h and 48h after surgery showed that pretreatment with 
ascorbate 3h before surgery did not attenuate the surgically-induced drop 
in aqueous ascorbate levels (Table 14A), although the plasma ascorbate 
concentration reached a maximum level within 2- 3h and remained elevated for 
about lOh before it fell to the preloaded concentration (Figure 19). Therefore, 
it seemed possible that the lack of an effect of ascorbate on Healon-induced 
IOP elevations postoperatively in the clinical situation may have been due to 
the failure to maintain elevated ascorbic acid levels in the anterior chamber, 
due to surgically-induced and Healon-induced damage to the blood-aqueous 
barrier.
Since the results of these rabbit studies suggested that ascorbic acid 
levels may decrease postoperatively, even with ascorbate pretreatment, 
experiments were conducted to determine whether the obstructive effect of 
Healon could be eliminated under conditions where a constant high
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concentration of ascorbate could be maintained.
The mechanism of IOP elevation is thought to involve a blockage of the 
outflow pathways and a consequent decrease in outflow facility (Berson et a l  
1983). Therefore, experiments were conducted in an in vitro human eye model 
designed to assess the effect of surgical and pharmacological manipulations on 
outflow facility. Initial studies were conducted to confirm that Healon 
decreases outflow facility. These studies, performed over a period of up to 
24h, showed that there was a concentration-dependent decrease in outflow 
facility due to Healon administration with a maximal decrease of 55% (Table 
12) occurring when the perfusion chamber was filled with the undiluted 
commercial preparation of Healon. The facility decrease was maximal within 
6h of administration, lasted for at least lh  and in some preparations persisted 
for 6h or more. The morphological correlate to these findings was the 
collection of Healon at the uveal surface of the TM which apparently blocked 
the egress of perfusion medium in much the same manner as the mechanical 
obstruction by cells, material or debris in some of the secondary forms of open 
angle glaucoma (eg, haemolytic, phacolytic, melanomalytic glaucoma, 
pigmentary glaucoma, exfoliative glaucoma, glaucoma due to hyphaema).
In some instances of the aforementioned studies in perfused anterior 
segments, the reduction in outflow facility was apparent immediately after the 
instillation of Healon into the perfusion chamber. In other cases, there was a 
delay of up to 6h before the maximum obstruction became apparent.
It is possible that on these occasions, when perfusion of culture medium 
was recommenced immediately after introduction of Healon into the chamber, 
small residues of medium remained trapped on the chamber walls from the pre- 
Healon perfusion, allowing formation of outflow channels of low-viscosity
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fluid. These would then presumably carry medium around the Healon to reach 
the trabecular meshwork with relatively little mixing with the highly viscous 
Healon. This might explain the observation that on two occasions (two eyes 
out of twelve in the 50% Healon group) the outflow facility did not rise until 
approximately 6h after the introduction of Healon.
In four preparations (two at the 10% and two at the 50% Healon) no 
obstruction was noted and actually the outflow facility slightly increased. The 
cause of the disparate results is not immediately apparent. There were no 
indications that cause of death or sex of the donor played a role. Although 
there was no apparent leakage from the injection point at the limbus through 
the course of these four experiments, technical difficulties cannot be ruled out. 
Alternatively, it is possible, like the clinical situation where Healon does not 
cause a postoperative IOP elevation in all patients, it does not cause obstruction 
in the outflow pathways of all eyes.
The significant decrease in outflow facility occurring with concentrations 
of Healon much lower (ie, 10% and 50%) than the commercial preparation, 
suggests that despite dilution of Healon at the end of cataract surgery, high 
postoperative IOP rises may be expected.
Similar to the Healon-induced rises in IOP observed in the clinical 
studies, Healon-induced reduction in outflow facility did not appear to improve 
in the presence of a constant high concentration of ascorbic acid 
(lOOOpg.ml'l) over a period of 6h (Table 16). Further study is necessary to 
confirm these preliminaiy findings.
Overall, the results of the in vitro studies confirm that the mechanism of 
the postoperative IOP elevation induced by Healon is a physical blockage of 
the aqueous humour outflow pathways. There is also clear evidence that this
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phenomenon is dose-related, which is consistent with the Healon dose- 
dependent rise in IOP observed in the clinical studies. Further, the failure of 
ascorbate to attenuate the Healon-induced IOP elevation in vivo was probably 
not due to insufficient levels of ascorbate in the aqueous humour, since the 
concentration used (1000pg.ml"l) in the perfused human ocular anterior 
segment preparation was at the top end of the range which can occur in vivo 
when oral ascorbate supplementation is used (Figure 21 A), and this level was 
not adequate to attenuate the Healon-induced reduction in outflow facility.
The mechanism by which ascorbate depolymerizes hyaluronate is thought 
to depend on trace quantities of Fe^+ amd Cu+ which are the actual catalysts 
of depolymerization. Ascorbate, presumably regenerates these ions to the 
appropriate reduced state, Fe^+ or Cu+ (Harris et al. 1972; Wong et al. 1981). 
Although hyaluronate can be depolymerized by ascorbate in vitro, the 
difference in origin and in the content of proteins and especially of heavy metal 
ions (eg, iron and copper) from the commercial preparation of Healon could be 
considerable and might influence the depolymerization reaction in either 
direction. Due to commercial confidentiality, Kabi Pharmacia is currently 
unwilling to divulge analytical data of this sort.
It is probable that either Healon is not depolymerized by ascorbate in 
vivo, or if it is, that depolymerization is not sufficient to break the hyaluronic 
acid molecules down to a size small enough to allow easy egress through the 
outflow pathways.
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5.2 SUGGESTIONS FOR FUTURE WORK
It is clear that although attempts have been made to attenuate Healon- 
induced IOP rises, either by anti- glaucoma drugs or by irrigating/aspirating 
Healon at the end of surgery, their success has been, at best, limited.
The present study showed that ascorbic acid pretreatment failed to 
prevent or to attenuate the immediate postoperative IOP elevation following the 
use of Healon during cataract surgery. Further study should be made on the 
involvement of heavy metal ions in the depolymerization reaction and on the 
levels of these ions occurring in normal and postoperative aqueous humour.
The finding that IOP rises were not as extreme when lower volumes of 
Healon were used intraoperatively has potentially important implications for 
the techniques employed in cataract surgery. Further clinical studies are 
recommended to verify the adequacy of using a low volume (<0.2ml) of 
Healon during cataract surgery.
A novel approach involving the use of hyaluronidase to depolymerize 
Healon has been suggested (Berson et a l  1983; Hein et a l  1986; Calder and 
Smith, 1986). Hyaluronidase has been used experimentally in cadaver human 
eyes. In enucleated eyes, anterior chamber irrigation with hyaluronidase 
showed a dramatic restoration toward normal of the reduced outflow facility 
following hyaluronate instillation (Berson et ah 1983). In an animal model, 
hyaluronate decreased outflow facility, but with a mixture of hyaluronate and 
hyaluronidase no significant change in outflow facility was noted (Hein et a l
1986). Calder et al (1986) found that the instillation of hyaluronidase into the 
anterior chamber in patients undergoing ICCE with IOL implantation resulted
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in a statistically significant lowering of postoperative IOP on the first and 
second postoperative days.
Although further research is needed to determine the smallest effective 
dose and to verify the safety of its use, the enzyme hyaluronidase shows 
promise as an effective treatment and it is suggested as a possible means of 
eliminating the potentially harmful postoperative IOP elevation following the 
use of Healon in cataract surgery.
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5.3 ADDENDUM TO DISCUSSION
5.3.1 Variation in the clinical trial
Several sources of variations may have contributed towards the 
variability of the data in the clinical ascorbate-Healon trial.
Many factors affect the amount of Healon remaining in the eye at the 
end of surgery. These are related:
a) to the volume, direction and speed of injection, and also to the angle 
and position of the cannula during the injection of Healon, and
b) to all these same factors during the irrigation/aspiration procedure by 
which the surgeon attempts to wash Healon out of the eye with 
Hartmann's solution.
All these factors combine to make it very difficult to estimate both 
the amount of Healon actually injected into the eye and the residual Healon 
volume. In a future study, the use of Healon Yellow would offer the 
opportunity to quantify the remaining amount of Healon, and the dynamics 
of its removal at the end of intraocular surgery. The technique of 
fluorophotometry potentially provides a method of quantification
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The lack of uniformity of the type of the incision during cataract 
surgery (limbal or comeal) may influence the postoperative IOP elevation 
(Rich et al,1974; Cherfan et_al,1983). A limbal section is more likely to 
lead to synthesis and release of prostaglandins, since the incision is 
performed through a vascular tissue and this may exacerbate the breakdown 
of the blood-aqueous barrier during the immediate postoperative period, 
resulting in higher IOP elevation. This is another source of variation which 
could be eliminated in a future study by ensuring that the same incision 
technique is used throughout.
However, in the present study similar percentages of each group 
underwent limbal and comeal incision. Further, regression analysis did not 
reveal any correlation between the type of the incision used and 
postoperative rise in IOP in any of the Healon groups.
The use of adrenaline (1 in 10"6) in Hartmann's solution is intended 
to prevent miosis during intraocular surgery. Since adrenaline from the 
irrigation solution may increase the facility of aqueous humour outflow, this 
could affect the postoperative IOP rise following cataract surgery. The 
influence of this factor upon the results obtained may, however, be 
negligible, since the concentration used is low and the same reagent was 
used uniformly throughout the present study. The volume of irrigating
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solution passing through the eye was not, however, measured in the present 
study and thus the total amount received by each operated eye cannot be 
estimated.
Further studies would be necessary to evaluate the role and the 
importance of the above factors.
5.3.2 The failure of ascorbic acid to prevent Healon-induced
intraocular pressure rise
A number of hypotheses may be invoked in order to explain the 
failure of ascorbic acid to prevent or attenuate postoperative IOP elevation 
following intraoperative use of Healon in cataract patients and to explain 
the failure of high constant concentration of ascorbic acid to reduce the 
Healon-induced decrease in aqueous humour outflow facility in the human 
eye model in vitro. These hypotheses are now presented and possible 
strategies to investigate them are described.
The mechanism of ascorbate-induced depolymerization of 
hyaluronate is unclear. There are several studies suggesting that hyaluronic 
acid of different origins (e.g. rooster comb, umbilical cord, synovial fluid) 
can be depolymerized by ascorbic acid in vitro and heavy metal ions may 
enhance this reaction (Niedermeier et a l 1967; Harris et ak 1972; Wong et 
al, 1981; Miyauchi and Iwata, 1984; Motohashi and Mori, 1985; Fink and 
Lengfelder, 1987). However, the depolymerization of the commercial 
preparation of sodium hyaluronate 1% (Healon) by ascorbic acid has not
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from the anterior chamber at the end of cataract surgery giving the 
appearance of "plastic anterior uveitis" (Cherfan et al, 1983; Larson et a l 
1989). This may be important in preventing ascorbic acid from penetrating 
a globule of unmixed, highly viscous Healon, thereby greatly reducing the 
rate of any depolymerization reaction. This hypothesis is supported by the 
fact that all previous in vitro experiments on the ascorbate-induced 
depolymerization of hyaluronate have been carried out following thorough 
mixing of the reagents.
In order to investigate this hypothesis, a study should be made on the 
effect of different concentrations of ascorbic acid solution on the reduction 
of aqueous outflow facility induced by low volumes of Healon, with and 
without thorough mixing with culture medium, in the perfused human eye 
model. The role and importance of heavy metal ions should also be studied 
in this preparation by adding different concentrations of these ions to the 
perfusion medium.
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APPENDIX
STATISTICAL ANALYSIS
The statistical analyses of all studies were earned out with Minitab 
statistical software for IBM PC.
Statistical analysis included: the two-tailed paired t- test, the two- 
tailed unpaired t-test, the chi-squared test, the Mann-Whitney U test, a 
simple regression analysis and a two-way analysis of variance.
P-value <0.05 was regarded as statistically significant.
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